

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ABALOPARATIDE

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ABATACEPT IV

Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ABATACEPT SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ABEMACICLIB

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ABIRATERONE

Products Affected

- *abiraterone acetate*
- *abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ABIRATERONE SUBMICRONIZED

Products Affected

- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ACALABRUTINIB

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: INTOLERANCE TO BRUKINSA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ADAGRASIB

Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ADALIMUMAB

Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ADALIMUMAB-AATY

Products Affected

- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>
Indications	All FDA-approved Indications.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan **2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ADALIMUMAB-ADBIM

Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AFATINIB

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ALECTINIB

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ALPELISIB-PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AMIKACIN LIPOSOMAL INH

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
Age Restrictions	
Prescriber Restrictions	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

AMIVANTAMAB-VMJW

Products Affected

- RYBREVANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ANAKINRA

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
Required Medical Information	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. CAPS, DIRA: NO CONCURRENT USE WITH OTHER IL-1

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	INHIBITORS. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

APALUTAMIDE

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

APOMORPHINE - ONAPGO

Products Affected

- ONAPGO

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

APOMORPHINE - SL

Products Affected

- KYNMOBI
- KYNMOBI TITRATION KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.
Prescriber Restrictions	PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

APREMILAST

Products Affected

- OTEZLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING 2 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., PUVA [PHOTOTHERAPY], UVB [ULTRAVIOLET LIGHT B], TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). RENEWAL: MILD PSO, BEHCETS DISEASE: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. MODERATE TO SEVERE PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ARIMOCLOMOL

Products Affected

- MIPLYFFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ASCIMINIB

Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML); MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ASFOTASE ALFA

Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ATOGEPANT

Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

AVACOPAN

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
Age Restrictions	
Prescriber Restrictions	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AVAPRITINIB

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AVUTOMETINIB-DEFACTINIB

Products Affected

- AVMAPKI FAKZYNJA CO-PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AXATILIMAB-CSFR

Products Affected

- NIKTIMVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

AXITINIB

Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

AZACITIDINE

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

AZTREONAM INHALED

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	7 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BEDAQUILINE

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 WEEKS
Other Criteria	PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB): SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MDR-TB.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BELIMUMAB

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BELUMOSUDIL

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

BELZUTIFAN

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BENDAMUSTINE

Products Affected

- BENDAMUSTINE HCL
INTRA VENOUS SOLUTION
- *bendamustine hcl intravenous solution
reconstituted*
- BENDEKA
- VIVIMUSTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BENRALIZUMAB

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): NO

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-2 INHIBITOR) FOR EGPA. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EGPA: 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EGPA
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

BETAINE

Products Affected

- *betaine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BEVACIZUMAB-ADCD

Products Affected

- VEGZELMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BEVACIZUMAB-AWWB

Products Affected

- MVASI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BEVACIZUMAB-BVZR

Products Affected

- ZIRABEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BEXAROTENE

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BINIMETINIB

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BORTEZOMIB

Products Affected

- *bortezomib injection*
- BORUZU

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BOSENTAN

Products Affected

- bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BOSUTINIB

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

BRIGATINIB

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

C1 ESTERASE INHIBITOR-HAEGARDA

Products Affected

- HAEGARDA SUBCUTANEOUS
SOLUTION RECONSTITUTED 2000
UNIT, 3000 UNIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTING: C1INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
Age Restrictions	
Prescriber Restrictions	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CABOZANTINIB CAPSULE

Products Affected

- COMETRIQ (100 MG DAILY DOSE)
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

CABOZANTINIB TABLET

Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CANNABIDIOL

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CAPIVASERTIB

Products Affected

- TRUQAP ORAL TABLET
- TRUQAP TABLET THERAPY PACK
160 MG ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CAPMATINIB

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CARGLUMIC ACID

Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
Other Criteria	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CERITINIB

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CERTOLIZUMAB PEGOL

Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL FOR PSA, PSO, AS, CD, NR-AXSPA, PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM MEDICATION.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CETUXIMAB

Products Affected

- ERBITUX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CLADRIBINE

Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	48 WEEKS.
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CLOBAZAM-SYMPAZAN

Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	LGS: 1) UNABLE TO TAKE TABLETS OR SUSPENSIONS, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF CLOBAZAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

COBIMETINIB

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CORTICOTROPIN

Products Affected

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML
- CORTROPHIN

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.
Coverage Duration	INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	Yes

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

CRIZOTINIB CAPSULE

Products Affected

- XALKORI ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

CRIZOTINIB PELLETS

Products Affected

- XALKORI ORAL CAPSULE SPRINKLE
150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DABRAFENIB CAPSULES

Products Affected

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DABRAFENIB SUSPENSION

Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNABLE TO SWALLOW TAFINLAR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DACOMITINIB

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DALFAMPRIDINE

Products Affected

- dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA. RENEWAL: IMPROVEMENT IN WALKING ABILITY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DAROLUTAMIDE

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MHSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DASATINIB

Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

DATOPOTAMAB DERUXTECAN-DLNK

Products Affected

- DATROWAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

DECITABINE/CEDAZURIDINE

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DEFERASIROX

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF DRY LIVER WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF DRY LIVER WEIGHT OR GREATER.
Age Restrictions	
Prescriber Restrictions	INITIAL (CHRONIC IRON OVERLOAD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL (CHRONIC IRON OVERLOAD): DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.
Indications	All FDA-approved Indications.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan **2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DENOSUMAB-XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DEUTETRABENAZINE

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DICLOFENAC TOPICAL SOLUTION

Products Affected

- *diclofenac sodium external solution 2 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1% TOPICAL GEL AND A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

DICLOFENAC-FLECTOR

Products Affected

- *diclofenac epolamine external*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DIROXIMEL FUMARATE

Products Affected

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DOSTARLIMAB-GXLY

Products Affected

- JEMPERLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DRONABINOL CAPSULE

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D FOR THE INDICATION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DROXIDOPA

Products Affected

- droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
Age Restrictions	
Prescriber Restrictions	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
Coverage Duration	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
Other Criteria	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DUPILUMAB

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. ATOPIC DERMATITIS (AD): AD COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR AD AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS.
Age Restrictions	
Prescriber Restrictions	AD, PN, CSU: PRESCRIBED OR IN CONSULTATION WITH DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST OR PULMONOLOGIST. CRSWNP: PRESCRIBED OR IN CONSULTATION WITH OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED OR IN CONSULTATION WITH GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED OR IN CONSULTATION WITH PULMONOLOGIST. RENEWAL: CSU: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: AD, CRSWNP, EOE, PN, CSU: 6 MOS, ASTHMA, COPD: 12 MOS. RENEWAL: ALL INDICATIONS: 12 MOS.
Other Criteria	INITIAL/RENEWAL: AD: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK INHIBITORS FOR AD. ASTHMA: NO CONCURRENT USE WITH XOLAIR, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: NO

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p> <p>EOSINOPHILIC COPD: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK-I FOR SAME INDICATION.</p> <p>INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID. PRURIGO NODULARIS (PN): 1) CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID OR CALCIPOTRIOL). EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

DUVELISIB

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

EFLORNITHINE

Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ELACESTRANT

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ELAGOLIX

Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.
Prescriber Restrictions	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
Other Criteria	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ELRANATAMAB-BCMM

Products Affected

- ELREXFIO SUBCUTANEOUS
SOLUTION 44 MG/1.1ML, 76
MG/1.9ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ELTROMBOPAG - ALVAIZ

Products Affected

- ALVAIZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS AND HAD A PRIOR BLEEDING EVENT.
Age Restrictions	
Prescriber Restrictions	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
Coverage Duration	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
Other Criteria	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ELTROMBOPAG - PROMACTA

Products Affected

- PROMACTA ORAL PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN $30 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT OF LESS THAN $50 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS AND A PRIOR BLEEDING EVENT.
Age Restrictions	
Prescriber Restrictions	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
Coverage Duration	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
Other Criteria	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. ALL INDICATIONS: APPROVAL FOR PROMACTA ORAL SUSPENSION PACKETS REQUIRES A TRIAL OF PROMACTA TABLET OR PATIENT IS UNABLE TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ENASIDENIB

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ENCORAFENIB

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ENTRECTINIB CAPSULES

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ENTRECTINIB PELLETS

Products Affected

- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ENZALUTAMIDE

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: ALL INDICATIONS: 12 MONTHS. RENEWAL: MCRPC, NMCRPC, MCSPC: 12 MONTHS.
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E. RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CRPC (MCRPC), NMCRPC, METASTATIC CSPC (MCSPC), NMCSPC : 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: MCRPC, NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

EPCORITAMAB-BYSP

Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

EPOETIN ALFA-EPBX

Products Affected

- RETACRIT INJECTION SOLUTION UNIT/ML, 4000 UNIT/ML, 40000
10000 UNIT/ML, 10000 UNIT/ML(1ML), UNIT/ML
2000 UNIT/ML, 20000 UNIT/ML, 3000

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS LESS THAN 13G/DL. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
Other Criteria	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ERDAFITINIB

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ERENUMAB-AOOE

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ERLOTINIB

Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ESKETAMINE

Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST.
Coverage Duration	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
Other Criteria	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ETANERCEPT

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

EVEROLIMUS-AFINITOR

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

EVEROLIMUS-AFINITOR DISPERZ

Products Affected

- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FECAL MICROBIOTA CAPSULE

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	30 DAYS
Other Criteria	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FEDRATINIB

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FENFLURAMINE

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	DRAVET SYNDROME: INITIAL/RENEWAL: 12 MONTHS. LGS: 12 MONTHS.
Other Criteria	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. RENEWAL: DRAVET SYNDROME: PATIENT HAS SHOWN CONTINUED CLINICAL BENEFIT (E.G. REDUCTION OF SEIZURES, REDUCED LENGTH OF SEIZURES, SEIZURE CONTROL MAINTAINED).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FENTANYL CITRATE

Products Affected

- fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FEZOLINETANT

Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) EXPERIENCES 7 OR MORE HOT FLASHES PER DAY, AND 2) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS). RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (I.E., PERSISTENT HOT FLASHES), AND 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FILGRASTIM-AAFI

Products Affected

- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FINERENONE

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FINGOLIMOD

Products Affected

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FOSCARBIDOPA-FOSLEVODOPA

Products Affected

- VYALEV SUBCUTANEOUS
SOLUTION 12-240 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	PD: INITIAL: 1) RESPONSIVE TO LEVODOPA, 2) CURRENT REGIMEN INCLUDES AT LEAST 400 MG/DAY OF LEVODOPA, AND 3) MOTOR SYMPTOMS ARE CURRENTLY UNCONTROLLED (DEFINED AS AN AVERAGE OFF TIME OF AT LEAST 2.5 HOURS/DAY OVER 3 CONSECUTIVE DAYS WITH A MINIMUM OF 2 HOURS EACH DAY). RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

FREMANEZUMAB-VFRM

Products Affected

- AJOVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

FRUQUINTINIB

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

FUTIBATINIB

Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GALCANEZUMAB-GNLM

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
Other Criteria	INITIAL: MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: MIGRAINE PREVENTION: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. EPISODIC CLUSTER HEADACHE: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GANAXOLONE

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GEFITINIB

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GILTERITINIB

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

GLASDEGIB

Products Affected

- DAURISMO ORAL TABLET 100 MG,
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GLATIRAMER

Products Affected

- *glatiramer acetate subcutaneous solution* • *glatopa subcutaneous solution prefilled*
prefilled syringe 20 mg/ml, 40 mg/ml *syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

GLP1-DULAGLUTIDE

Products Affected

- TRULICITY SUBCUTANEOUS
SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

GLP1-SEMAGLUTIDE

Products Affected

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

GLP1-TIRZEPATIDE

Products Affected

- MOUNJARO SUBCUTANEOUS
SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GOSERELIN

Products Affected

- ZOLADEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	
Prescriber Restrictions	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
Other Criteria	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

GUSELKUMAB

Products Affected

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IBRUTINIB

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ICATIBANT

Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING.
Age Restrictions	
Prescriber Restrictions	HAE: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HAE: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR TREATMENT OF ACUTE HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IDELALISIB

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IMATINIB

Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

IMATINIB SOLUTION

Products Affected

- IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IMETELSTAT

Products Affected

- RYTELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INAVOLISIB

Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INFLIXIMAB

Products Affected

- infliximab*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.</p>
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INSULIN SUPPLIES PAYMENT DETERMINATION

Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 0.5 ML (OTC)
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|--|--|
| • AUM MINI INSULIN PEN NEEDLE 33G X 4 MM | • BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX) |
| • AUM MINI INSULIN PEN NEEDLE 33G X 5 MM | • BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML |
| • AUM MINI INSULIN PEN NEEDLE 33G X 6 MM | • BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML |
| • AUM PEN NEEDLE 32G X 4 MM | • BD INSULIN SYRINGE MICROFINE 28G X 1/2" 0.5 ML |
| • AUM PEN NEEDLE 32G X 5 MM | • BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC) |
| • AUM PEN NEEDLE 32G X 6 MM | • BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX) |
| • AUM PEN NEEDLE 33G X 4 MM | • BD INSULIN SYRINGE U-100 1 ML |
| • AUM PEN NEEDLE 33G X 5 MM | • BD INSULIN SYRINGE U-500 |
| • AUM PEN NEEDLE 33G X 6 MM | • BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML |
| • AUM READYGARD DUO PEN NEEDLE 32G X 4 MM | • BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML |
| • AUM SAFETY PEN NEEDLE 31G X 4 MM | • BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 1 ML |
| • BD AUTOSHIELD 29G X 5MM | • BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML |
| • BD AUTOSHIELD 29G X 8MM | • BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML |
| • BD AUTOSHIELD DUO 30G X 5 MM | • BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.3 ML |
| • BD ECLIPSE SYRINGE 30G X 1/2" 1 ML | • BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.5 ML |
| • BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML | • BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM |
| • BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML | • BD PEN NEEDLE MINI U/F 31G X 5 MM |
| • BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML | • BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM |
| • BD INSULIN SYRINGE 27.5G X 5/8" 2 ML | • BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM |
| • BD INSULIN SYRINGE 25G X 1" 1 ML | • BD PEN NEEDLE NANO U/F 32G X 4 MM |
| • BD INSULIN SYRINGE 25G X 5/8" 1 ML | • BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM |
| • BD INSULIN SYRINGE 26G X 1/2" 1 ML | • BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM |
| • BD INSULIN SYRINGE 27G X 1/2" 1 ML | |
| • BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC) | |
| • BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX) | |
| • BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC) | |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|--|--|
| • BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM | • CAREFINE PEN NEEDLES 31G X 6 MM |
| • BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2" 1 ML | • CAREFINE PEN NEEDLES 31G X 8 MM |
| • BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML | • CAREFINE PEN NEEDLES 32G X 4 MM |
| • BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.5 ML | • CAREFINE PEN NEEDLES 32G X 5 MM |
| • BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML | • CAREFINE PEN NEEDLES 32G X 6 MM |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML | • CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML | • CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML | • CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML | • CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML | • CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • BD SWAB SINGLE USE REGULAR PAD | • CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML |
| • BD SWABS SINGLE USE BUTTERFLY PAD | • CARETOUCH ALCOHOL PREP PAD 70 % |
| • BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML | • CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML | • CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML | • CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML | • CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML |
| • CAREFINE PEN NEEDLES 29G X 12MM | • CARETOUCH PEN NEEDLES 29G X 12MM |
| • CAREFINE PEN NEEDLES 30G X 8 MM | • CARETOUCH PEN NEEDLES 31G X 5 MM |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|---|--|
| • CARETOUCH PEN NEEDLES 31G X 6 MM | • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • CARETOUCH PEN NEEDLES 31G X 8 MM | • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML |
| • CARETOUCH PEN NEEDLES 32G X 4 MM | • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML |
| • CARETOUCH PEN NEEDLES 32G X 5 MM | • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML |
| • CARETOUCH PEN NEEDLES 33G X 4 MM | • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML |
| • CLEVER CHOICE COMFORT EZ 29G X 12MM | • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • CLEVER CHOICE COMFORT EZ 33G X 4 MM | • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • CLICKFINE PEN NEEDLES 31G X 6 MM | • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML |
| • CLICKFINE PEN NEEDLES 31G X 8 MM | • COMFORT EZ PEN NEEDLES 31G X 5 MM |
| • CLICKFINE PEN NEEDLES 32G X 4 MM | • COMFORT EZ PEN NEEDLES 31G X 6 MM |
| • COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML | • COMFORT EZ PEN NEEDLES 31G X 8 MM |
| • COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML | • COMFORT EZ PEN NEEDLES 32G X 4 MM |
| • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML | • COMFORT EZ PEN NEEDLES 32G X 5 MM |
| • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML | • COMFORT EZ PEN NEEDLES 32G X 6 MM |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML | • COMFORT EZ PEN NEEDLES 32G X 8 MM |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML | • COMFORT EZ PEN NEEDLES 33G X 4 MM |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML | • COMFORT EZ PEN NEEDLES 33G X 5 MM |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML | • COMFORT EZ PEN NEEDLES 33G X 6 MM |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML | • COMFORT EZ PEN NEEDLES 33G X 8 MM |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML | • COMFORT EZ PRO PEN NEEDLES 30G X 8 MM |
| • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML | • COMFORT EZ PRO PEN NEEDLES 31G X 4 MM |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|---|---|
| • COMFORT EZ PRO PEN NEEDLES 31G X 5 MM | • DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML |
| • COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM | • DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML |
| • COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM | • DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML |
| • COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM | • DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML |
| • COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM | • DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML |
| • COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM | • DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML |
| • COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM | • DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML |
| • COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM | • DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML |
| • COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM | • DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML |
| • CURITY ALCOHOL PREPS PAD 70 % | • DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML |
| • CURITY ALL PURPOSE SPONGES PAD 2"X2" | • DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • CURITY GAUZE PAD 2"X2" | • DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML |
| • CURITY GAUZE SPONGE PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 1/4" 0.3 ML |
| • CURITY SPONGES PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 1/4" 0.5 ML |
| • CVS GAUZE PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 1/4" 1 ML |
| • CVS GAUZE STERILE PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML |
| • DERMACEA GAUZE SPONGE PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML |
| • DERMACEA IV DRAIN SPONGES PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 15/64" 1 ML |
| • DERMACEA NON-WOVEN SPONGES PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • DERMACEA TYPE VII GAUZE PAD 2"X2" | • DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • DIATHRIVE PEN NEEDLE 31G X 5 MM | • DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML |
| • DIATHRIVE PEN NEEDLE 31G X 6 MM | • DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • DIATHRIVE PEN NEEDLE 31G X 8 MM | • DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • DIATHRIVE PEN NEEDLE 32G X 4 MM | • DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 29G X 4MM
- EASY COMFORT PEN NEEDLES 29G X 5MM
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|--|---|
| • EASY COMFORT PEN NEEDLES 32G X 4 MM | • EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML |
| • EASY COMFORT PEN NEEDLES 33G X 4 MM | • EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML |
| • EASY COMFORT PEN NEEDLES 33G X 5 MM | • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML |
| • EASY COMFORT PEN NEEDLES 33G X 6 MM | • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML |
| • EASY GLIDE PEN NEEDLES 33G X 4 MM | • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML |
| • EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 % | • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML |
| • EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML | • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML | • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML |
| • EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML | • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML | • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML | • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML |
| • EASY TOUCH INSULIN BARRELS U-100 1 ML | • EASY TOUCH PEN NEEDLES 29G X 12MM |
| • EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 30G X 5 MM |
| • EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 30G X 6 MM |
| • EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 30G X 8 MM |
| • EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML | • EASY TOUCH PEN NEEDLES 31G X 5 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 31G X 6 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 31G X 8 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML | • EASY TOUCH PEN NEEDLES 32G X 4 MM |
| • EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 32G X 5 MM |
| • EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 32G X 6 MM |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-100 28G X 1/2" 1 ML
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- FREESTYLE PRECISION INS SYR 30G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 30G X 5/16" 1 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 1 ML
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD
- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGE 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GOODSENSE ALCOHOL SWABS PAD 70 %
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE ALCOHOL PREP PAD
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)
- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 31G X 8 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN SENSITIVE 32G X 6 MM
- INSUPEN SENSITIVE 32G X 8 MM
- INSUPEN ULTRAFIN 29G X 12MM
- INSUPEN ULTRAFIN 30G X 8 MM
- INSUPEN ULTRAFIN 31G X 6 MM
- INSUPEN ULTRAFIN 31G X 8 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 8 MM
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM
- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 4 MM (OTC)
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 1 ML
- PRECISION SURE-DOSE SYRINGE 29G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 3/8" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 31G X 8 MM
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELI-ON INSULIN SYRINGE 29G 0.5 ML
- RELI-ON INSULIN SYRINGE 29G X 1/2" 1 ML
- RELION ALCOHOL SWABS PAD
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE-PREP ALCOHOL PREP PAD 70 %
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TECHLITE PEN NEEDLES 32G X 4 MM
- TERUMO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|---|---|
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM | • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM | • ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM | • ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM | • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML |
| • TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML | • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML |
| • TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML | • ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML | • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML | • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML | • ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC) |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX) |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML | • ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML |
| • TRUEPLUS PEN NEEDLES 29G X 12MM | • ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML |
| • TRUEPLUS PEN NEEDLES 31G X 5 MM | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC) |
| • TRUEPLUS PEN NEEDLES 31G X 6 MM | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX) |
| • TRUEPLUS PEN NEEDLES 31G X 8 MM | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC) |
| • TRUEPLUS PEN NEEDLES 32G X 4 MM | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX) |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML |

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- | | |
|---|--|
| <ul style="list-style-type: none"> • ULTICARE MICRO PEN NEEDLES 32G X 4 MM • ULTICARE MINI PEN NEEDLES 30G X 5 MM • ULTICARE MINI PEN NEEDLES 31G X 6 MM • ULTICARE MINI PEN NEEDLES 32G X 6 MM • ULTICARE PEN NEEDLES 29G X 12.7MM (OTC) • ULTICARE PEN NEEDLES 29G X 12.7MM (RX) • ULTICARE PEN NEEDLES 31G X 5 MM • ULTICARE SHORT PEN NEEDLES 30G X 8 MM • ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC) • ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX) • ULTIGUARD SAFEPAK PEN NEEDLE 29G X 12.7MM • ULTIGUARD SAFEPAK PEN NEEDLE 31G X 5 MM • ULTIGUARD SAFEPAK PEN NEEDLE 31G X 6 MM • ULTIGUARD SAFEPAK PEN NEEDLE 31G X 8 MM • ULTIGUARD SAFEPAK PEN NEEDLE 32G X 4 MM • ULTIGUARD SAFEPAK PEN NEEDLE 32G X 6 MM • ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.3 ML • ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.5 ML • ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 1 ML • ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.3 ML • ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.5 ML | <ul style="list-style-type: none"> • ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 1 ML • ULTILET ALCOHOL SWABS PAD • ULTILET INSULIN SYRINGE 30G X 1/2" 0.5 ML • ULTILET INSULIN SYRINGE 30G X 1/2" 1 ML • ULTILET INSULIN SYRINGE 30G X 5/16" 0.3 ML • ULTILET INSULIN SYRINGE 30G X 5/16" 0.5 ML • ULTILET INSULIN SYRINGE 30G X 5/16" 1 ML • ULTILET INSULIN SYRINGE 31G X 1/4" 0.3 ML • ULTILET INSULIN SYRINGE 31G X 1/4" 1 ML • ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (OTC) • ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (RX) • ULTILET INSULIN SYRINGE 31G X 15/64" 0.5 ML • ULTILET INSULIN SYRINGE 31G X 5/16" 0.3 ML • ULTILET INSULIN SYRINGE 31G X 5/16" 1 ML • ULTILET INSULIN SYRINGE SHORT 30G X 1/2" 0.3 ML • ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.3 ML • ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.5 ML • ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 1 ML • ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.3 ML • ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.5 ML • ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 1 ML • ULTILET PEN NEEDLE 29G X 12.7MM |
|---|--|

Y0135 PA25 C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	LIFETIME
Other Criteria	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INTERFERON FOR MS-AVONEX

Products Affected

- AVONEX PEN INTRAMUSCULAR
 AUTO-INJECTOR KIT
- AVONEX PREFILLED
 INTRAMUSCULAR PREFILLED
 SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INTERFERON FOR MS-BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INTERFERON FOR MS-PLEGRIDY

Products Affected

- PLEGRIDY STARTER PACK
SUBCUTANEOUS SOLUTION AUTO-
INJECTOR
- PLEGRIDY STARTER PACK
SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS
SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS
SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

INTERFERON GAMMA-1B

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPECTOSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IPILIMUMAB

Products Affected

- YERVOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
Other Criteria	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IVACAFTOR

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS
Age Restrictions	
Prescriber Restrictions	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
Other Criteria	CF: INITIAL: NOT HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE. RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

IVOSIDENIB

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

IXAZOMIB

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LANREOTIDE

Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT
SUBCUTANEOUS SOLUTION 60
MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	ACROMEGALY: INITIAL: 3 MOS, RENEWAL: 12 MOS.GEP-NETS, CARCINOID SYNDROME: 12 MOS.
Other Criteria	ACROMEGALY: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE GENERIC OCTREOTIDE INJECTION. RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LAPATINIB

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LAROTRECTINIB

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

LAZERTINIB

Products Affected

- LAZCLUZE ORAL TABLET 240 MG,
80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEDIPASVIR-SOFOSBUVIR

Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. REQUESTS FOR HARVONI 45MG-200MG PELLETS: PATIENT IS UNABLE TO SWALLOW TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LENALIDOMIDE

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LENVATINIB

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LETERMOVIR

Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
Other Criteria	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEUPROLIDE

Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEUPROLIDE DEPOT

Products Affected

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEUPROLIDE-ELIGARD

Products Affected

- ELIGARD

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEUPROLIDE-LUPRON DEPOT

Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
Other Criteria	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LEUPROLIDE-LUPRON DEPOT-PED

Products Affected

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVELS OF FOLLICLE-STIMULATING HORMONE (FSH) GREATER THAN 4.0 MIU/ML AND LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVELS OF FSH GREATER THAN 5.0 MIU/ML AND LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
Age Restrictions	
Prescriber Restrictions	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

L-GLUTAMINE

Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
Other Criteria	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LIDOCAINE OINTMENT

Products Affected

- *lidocaine external ointment 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LIDOCAINE PATCH

Products Affected

- *lidocaine external patch 5 %*
- *lidocan*
- ZTLIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1) PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA, 2) NEUROPATHY DUE TO DIABETES MELLITUS, 3) CHRONIC BACK PAIN, OR 4) OSTEOARTHRITIS OF THE KNEE OR HIP.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LIDOCAINE PRILOCAINE

Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

LONCASTUXIMAB TESIRINE-LPYL

Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LORLATINIB

Products Affected

- LORBRENA ORAL TABLET 100 MG,
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LOTILANER

Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	6 WEEKS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

LUMACAFITOR-IVACAFITOR

Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CYSTIC FIBROSIS (CF): CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CF.
Age Restrictions	
Prescriber Restrictions	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: LIFETIME.
Other Criteria	CF: RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MACITENTAN

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MARGETUXIMAB-CMKB

Products Affected

- MARGENZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MARIBAVIR

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MECASERMIN

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. RENEWAL: IMPROVEMENT WHILE ON THERAPY (I.E., INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MECHLORETHAMINE

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MEPOLIZUMAB

Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST.
Coverage Duration	INITIAL: ASTHMA: 12 MO. CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA: 12 MO.
Other Criteria	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MIDOSTAURIN

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MIFEPRISTONE

Products Affected

- mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (2 OR MORE TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (2 OR MORE TESTS TO CONFIRM).
Age Restrictions	
Prescriber Restrictions	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE, ETC.), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MILTEFOSINE

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MIRDAMETINIB

Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MIRVETUXIMAB SORAVTANSINE-GYNX

Products Affected

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MOMELOTINIB

Products Affected

- OJAARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

MOSUNETUZUMAB-AXGB

Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NARCOLEPSY AGENTS

Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NAXITAMAB-GQGK

Products Affected

- DANYELZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NERATINIB

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NILOTINIB

Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND TASIGNA IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NILOTINIB-DANZITEN

Products Affected

- DANZITEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NINTEDANIB

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) BASELINE FORCED VITAL CAPACITY (FVC) AT LEAST 50% OF PREDICTED VALUE. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 45% OF PREDICTED VALUE.
Age Restrictions	
Prescriber Restrictions	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
Other Criteria	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G.,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ACTEMRA SUBQ. PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERD/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIRAPARIB

Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIRAPARIB-ABIRATERONE

Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIROGACESTAT

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NITISINONE

Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.
Age Restrictions	
Prescriber Restrictions	HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIVOLUMAB

Products Affected

- OPDIVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIVOLUMAB-HYALURONIDASE-NVHY

Products Affected

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

NIVOLUMAB-RELATLIMAB-RMBW

Products Affected

- OPDUALAG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

NOGAPENDEKIN ALFA

Products Affected

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	40 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OCRELIZUMAB

Products Affected

- OCREVUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OCRELIZUMAB-HYALURONIDASE-OCSQ

Products Affected

- OCREVUS ZUNOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OFATUMUMAB-SQ

Products Affected

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

OLANZAPINE/SAMIDORPHAN

Products Affected

- LYBALVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SCHIZOPHRENIA, BIPOLAR I: PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST
Coverage Duration	12 MONTHS
Other Criteria	SCHIZOPHRENIA: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF LURASIDONE OR ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. BIPOLAR I: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OLAPARIB

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OLUTASIDENIB

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

OMACETAXINE

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OMALIZUMAB

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) ALLERGEN SPECIFIC IGE SERUM LEVEL OF AT LEAST 6 KUA/L TO AT LEAST ONE FOOD, OR POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
Age Restrictions	
Prescriber Restrictions	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
Coverage Duration	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
Other Criteria	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ONE PREFERRED AGENT: NUCALA, DUPIXENT, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. FOOD ALLERGY: 1) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 2) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 3) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OSIMERTINIB

Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

OXANDROLONE

Products Affected

- *oxandrolone oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PACRITINIB

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PALBOCICLIB

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE PREFERRED AGENTS, WHERE INDICATIONS ALIGN: KISQALI, VERZENIO.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PARATHYROID HORMONE

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: 1) TRIAL OF OR CONTRAINDICATION TO CALCITRIOL, 2) HYPOPARATHYROIDISM IS NOT DUE TO A CALCIUM SENSING RECEPTOR (CSR) MUTATION, AND 3) HYPOPARATHYROIDISM IS NOT CONSIDERED ACUTE POST-SURGICAL HYPOPARATHYROIDISM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PASIREOTIDE DIASPARTATE

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PAZOPANIB

Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEGFILGRASTIM - APGF

Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEGFILGRASTIM-NEULASTA ONPRO

Products Affected

- NEULASTA ONPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEGINTERFERON ALFA-2A

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
Coverage Duration	HEP B/HEP C: 48 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEGVISOMANT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEMBROLIZUMAB

Products Affected

- KEYTRUDA INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEMIGATINIB

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PENICILLAMINE TABLET

Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
Age Restrictions	
Prescriber Restrictions	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PEXIDARTINIB

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PIMAVANSERIN

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
Prescriber Restrictions	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50% AT BASELINE.
Age Restrictions	IPF: INITIAL: 18 YEARS OR OLDER.
Prescriber Restrictions	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PIRTOBRUTINIB

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

POMALIDOMIDE

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PONATINIB

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

POSACONAZOLE TABLET

Products Affected

- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PRALSETINIB

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PYRIMETHAMINE

Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
Other Criteria	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

QUININE

Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

QUIZARTINIB

Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

REGORAFENIB

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RELUGOLIX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

REPOTRECTINIB

Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RESLIZUMAB

Products Affected

- CINQAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	ASTHMA: INITIAL: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, 3) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: FASENRA, NUCALA, DUPIXENT, AND 4) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. RENEWAL: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RETIFANLIMAB-DLWR

Products Affected

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

REVUMENIB

Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RIBOCICLIB

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RIBOCICLIB-LETROZOLE

Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

RIFAXIMIN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
Other Criteria	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RILONACEPT

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
Other Criteria	CAPS: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS. DIRA: 1) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RILUZOLE

Products Affected

- TIGLUTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

RIMEGEPANT

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	<p>INITIAL: ACUTE MIGRAINE TREATMENT: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: ACUTE MIGRAINE TREATMENT: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY,</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RIOCIGUAT

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
Indications	All FDA-approved Indications.

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RIPRETINIB

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RISANKIZUMAB-RZAA

Products Affected

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RITUXIMAB AND HYALURONIDASE HUMAN-SQ

Products Affected

- RITUXAN HYCELA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RITUXIMAB-ABBS

Products Affected

- TRUXIMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RITUXIMAB-ARRX

Products Affected

- RIABNI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS (RA): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RITUXIMAB-PVVR

Products Affected

- RUXIENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	RA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ROPEGINTERFERON ALFA-2B-NJFT

Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RUCAPARIB

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

RUXOLITINIB

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SAPROPTERIN

Products Affected

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
Other Criteria	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SECUKINUMAB IV

Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1)

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SECUKINUMAB SQ

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. RENEWAL: PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA, HS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SELEXIPAG

Products Affected

- UPTRAVI INTRAVENOUS
- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SELINEXOR

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG
- XPOVIO (40 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 10
MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (60 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 60
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

SELPERCATINIB

Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SELUMETINIB

Products Affected

- KOSELUGO ORAL CAPSULE 10 MG,
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SILDENAFIL TABLET

Products Affected

- sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
Indications	All Medically-accepted Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SIPONIMOD

Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SIROLIMUS PROTEIN-BOUND

Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SODIUM OXYBATE-XYREM

Products Affected

- sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY, AND 3) AGES 7 TO 17 YEARS: TRIAL, FAILURE OF, OR CONTRAINDICATION TO ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SOFOSBUVIR/VELPATASVIR

Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANAVIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SOMATROPIN - NORDITROPIN

Products Affected

- NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
Required Medical Information	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), TURNER SYNDROME (TS), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS.
Age Restrictions	
Prescriber Restrictions	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: ADULT GHD: GHD ALONE OR ASSOCIATED WITH MULTIPLE HORMONE DEFICIENCIES (HYPOPITUITARISM), AS A RESULT OF PITUITARY DISEASE, HYPOTHALAMIC DISEASE, SURGERY, RADIATION THERAPY, OR TRAUMA, OR FOR CONTINUATION OF THERAPY FROM CHILDHOOD ONSET GHD. PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. RENEWAL: PEDIATRIC GHD: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. ISS, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (I.E.,

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PWS: IMPROVEMENT IN BODY COMPOSITION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SOMATROPIN - SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS
 SOLUTION RECONSTITUTED 4 MG, 5
 MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
Required Medical Information	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 2) 7.5% UNINTENTIONAL WEIGHT LOSS OVER 6 MONTHS, 3) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 4) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 5) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 6) BMI LESS THAN 18.5 KG PER METER SQUARED.
Age Restrictions	
Prescriber Restrictions	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	INITIAL/RENEWAL: 3 MONTHS.
Other Criteria	HIV/WASTING: INITIAL: 1) INADEQUATE RESPONSE TO ONE PREVIOUS THERAPY (E.G., MEGACE, APPETITE STIMULANTS, ANABOLIC STEROIDS). RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SONIDEGIB

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SORAFENIB

Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SOTATERCEPT-CSRK

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

SOTORASIB

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

STIRIPENTOL

Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

SUNITINIB

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB (GLEEVEC).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TADALAFIL - ADCIRCA, ALYQ

Products Affected

- *alyq*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TADALAFIL-CIALIS

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TALAZOPARIB

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TALQUETAMAB-TGVS

Products Affected

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TARLATAMAB-DLLE

Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TAZEMETOSTAT

Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TEBENTAFUSP-TEBN

Products Affected

- KIMMTRAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TECLISTAMAB-CQYV

Products Affected

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TELISOTUZUMAB VEDOTIN-TLLV

Products Affected

- EMRELIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TELOTRISTAT

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TEPOTINIB

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TERIPARATIDE

Products Affected

- TERIPARATIDE SUBCUTANEOUS
 SOLUTION PEN-INJECTOR 620
 MCG/2.48ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
 Formulary ID: 25261
 Last Updated: 06/27/2025
 Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TESTOSTERONE

Products Affected

- testosterone gel 1.62 % transdermal
- testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TESTOSTERONE CYPIONATE

Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TESTOSTERONE ENANTHATE

Products Affected

- *testosterone enanthate intramuscular solution*
- XYOSTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
Other Criteria	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TETRABENAZINE

Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

THALIDOMIDE

Products Affected

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TISLELIZUMAB-JSGR

Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TISOTUMAB VEDOTIN-TFTV

Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TIVOZANIB

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOCILIZUMAB IV

Products Affected

- ACTEMRA

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOCILIZUMAB SQ

Products Affected

- ACTEMRA
- ACTEMRA ACTPEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan **2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS). RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOCILIZUMAB-AAZG

Products Affected

- TYENNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOCILIZUMAB-AAZG IV

Products Affected

- TYENNE

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: RA, PJIA, SJIA, GCA: 6 MOS. CRS: 1 MO. RENEWAL: RA, PJIA, SJIA, GCA: 12 MOS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. CYTOKINE RELEASE SYNDROME (CRS): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CRS. INITIAL/RENEWAL FOR PJIA, SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SAME INDICATION. RENEWAL FOR RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM MEDICATION.
Indications	All FDA-approved Indications.

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOFACITINIB

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PCJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. UC: NO CONCURRENT

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PCJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOPICAL TRETINOIN

Products Affected

- ALTRENO
- *tretinoin external cream*

PA Criteria	Criteria Details
Exclusion Criteria	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TORIPALIMAB-TPZI

Products Affected

- LOQTORZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TOVORAFENIB

Products Affected

- OJEMDA ORAL SUSPENSION • OJEMDA ORAL TABLET
- RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRAMADOL

Products Affected

- TRAMADOL HCL ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRAMETINIB SOLUTION

Products Affected

- MEKINIST ORAL SOLUTION
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG); UNABLE TO SWALLOW MEKINIST TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TRAMETINIB TABLET

Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TRASTUZUMAB-DKST

Products Affected

- OGIVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRASTUZUMAB-DTTB

Products Affected

- ONTRUZANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRASTUZUMAB-HYALURONIDASE-OYSK

Products Affected

- HERCEPTIN HYLECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRASTUZUMAB-PKRB

Products Affected

- HERZUMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRASTUZUMAB-QYYP

Products Affected

- TRAZIMERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRAZODONE

Products Affected

- RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MAJOR DEPRESSIVE DISORDER (MDD): CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TREMELIMUMAB-ACTL

Products Affected

- IMJUDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
Other Criteria	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TRIENTINE CAPSULE

Products Affected

- trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	WILSONS DISEASE: INITIAL: 1) LEIPZIG SCORE OF 4 OR GREATER, AND 2) TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TRIFLURIDINE/TIPIRACIL

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG,
20-8.19 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

TRIPTORELIN-TRELSTAR

Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

TUCATINIB

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

UBROGEPANT

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

UPADACITINIB

Products Affected

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). ATOPIC DERMATITIS (AD): ATOPIC DERMATITIS COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR ATOPIC DERMATITIS AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR, AND 3) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITORS FOR ANY INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG), AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITOR FOR ANY INDICATION. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC</p>

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB IV

Products Affected

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	2 MONTHS
Other Criteria	CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB-AEKN IV

Products Affected

- SELARSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB-AEKN SQ

Products Affected

- SELARSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB-KFCE IV

Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

USTEKINUMAB-KFCE SQ

Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135_PA25_C

Formulary ID: 25261

Last Updated: 06/27/2025

Effective: 07/01/2025

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VALBENAZINE

Products Affected

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VANDETANIB

Products Affected

- CAPRELSA ORAL TABLET 100 MG,
300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

VANZACAFTOR-TEZACAFTOR- DEUTIVACAFTOR

Products Affected

- ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
Other Criteria	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VEMURAFENIB

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VENETOCLAX

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VERICIGUAT

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL:12 MONTHS.
Other Criteria	HEART FAILURE (HF): INITIAL: 1) NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIQUAT, OR PDE-5 INHIBITORS, 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED SGLT-2 INHIBITOR, AND 3) TRIAL OF OR CONTRAINDICATION TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (I.E., BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (I.E., SPIRONOLACTONE, EPLERENONE). RENEWAL: NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIQUAT, OR PDE-5 INHIBITORS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VIGABATRIN

Products Affected

- *vigabatrin*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	CPS: TRIAL OF OR CONTRAINDICATION TO TWO ANTIEPILEPTIC AGENTS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VIMSELTINIB

Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VISMODEGIB

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VORASIDENIB

Products Affected

- VORANIGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

VORICONAZOLE SUSPENSION

Products Affected

- voriconazole oral suspension reconstituted*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
Other Criteria	CANDIDA INFECTIONS: 1) TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE, AND 2) UNABLE TO SWALLOW TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ZANIDATAMAB-HRII

Products Affected

- ZIIHERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ZANUBRUTINIB

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ZENOCUTUZUMAB-ZBCO

Products Affected

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria

ZOLBETUXIMAB-CLZB

Products Affected

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

**Provider Partners Health Plan
2025 Formulary – Prior Authorization Criteria**

ZURANOLONE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 DAYS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135_PA25_C
Formulary ID: 25261
Last Updated: 06/27/2025
Effective: 07/01/2025

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

INDEX

A

abiraterone acetate	7	ALCOHOL SWABS PAD 70 %	161, 181
abirtega.....	7	ALECENSA.....	21
ABOUTTIME PEN NEEDLE 30G X 8 MM	161, 181	ALTRENO.....	364
ABOUTTIME PEN NEEDLE 31G X 5 MM	161, 181	ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG.....	60
ABOUTTIME PEN NEEDLE 31G X 8 MM	161, 181	ALUNBRIG ORAL TABLET THERAPY PACK.....	60
ABOUTTIME PEN NEEDLE 32G X 4 MM	161, 181	ALVAIZ.....	107
ACTEMRA.....	354, 355, 356, 357	ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG	398
ACTEMRA ACTPEN	356, 357	alyq.....	334
ACTHAR	75, 76	ANKTIVA	241
ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML	75, 76	AQ INSULIN SYRINGE 31G X 5/16... 161, 181	
ACTIMMUNE.....	185	AQINJECT PEN NEEDLE 31G X 5 MM	161, 181
ADEMPAS	294, 295	AQINJECT PEN NEEDLE 32G X 4 MM	161, 181
ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM.....	161, 181	ARCALYST	289, 290
ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM.....	161, 181	ARIKAYCE.....	23
ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM.....	161, 181	armodafinil.....	227
ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM.....	161, 181	ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM.....	161, 181
ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM.....	161, 181	ASSURE ID INSULIN SAFETY SYR 29G X 1/2.....	161, 181
ADVOCATE INSULIN SYRINGE 29G X 1/2	161, 181	ASSURE ID INSULIN SAFETY SYR 31G X 15/64.....	161, 181
ADVOCATE INSULIN SYRINGE 30G X 5/16	161, 181	ASSURE ID PRO PEN NEEDLES 30G X 5 MM	161, 181
ADVOCATE INSULIN SYRINGE 31G X 5/16	161, 181	AUGTYRO ORAL CAPSULE 160 MG, 40 MG	281
AIMOVIG.....	120	AUM ALCOHOL PREP PADS PAD 70 %	161, 181
AJOVY	136	AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM.....	161, 181
AKEEGA	235	AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM.....	161, 181
ALCOHOL PREP PAD.....	161, 181	AUM MINI INSULIN PEN NEEDLE 32G X 4 MM.....	161, 181
ALCOHOL PREP PAD 70 %.....	161, 181	AUM MINI INSULIN PEN NEEDLE 32G X 5 MM.....	161, 181
ALCOHOL PREP PADS PAD 70 % 161, 181		AUM MINI INSULIN PEN NEEDLE 32G X 6 MM.....	161, 181
ALCOHOL SWABS PAD.....	161, 181		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

AUM MINI INSULIN PEN NEEDLE 32G X 8 MM..... 161, 181	BD INSULIN SYRINGE 25G X 5/8..... 162, 181
AUM MINI INSULIN PEN NEEDLE 33G X 4 MM..... 162, 181	BD INSULIN SYRINGE 26G X 1/2..... 162, 181
AUM MINI INSULIN PEN NEEDLE 33G X 5 MM..... 162, 181	BD INSULIN SYRINGE 27.5G X 5/8.. 162, 181
AUM MINI INSULIN PEN NEEDLE 33G X 6 MM..... 162, 181	BD INSULIN SYRINGE 27G X 1/2..... 162, 181
AUM PEN NEEDLE 32G X 4 MM 162, 181	BD INSULIN SYRINGE 29G X 1/2..... 162, 181
AUM PEN NEEDLE 32G X 5 MM 162, 181	BD INSULIN SYRINGE HALF-UNIT 31G X 5/16..... 162, 181
AUM PEN NEEDLE 32G X 6 MM 162, 181	BD INSULIN SYRINGE MICROFINE 27G X 5/8..... 162, 181
AUM PEN NEEDLE 33G X 4 MM 162, 181	BD INSULIN SYRINGE MICROFINE 28G X 1/2..... 162, 181
AUM PEN NEEDLE 33G X 5 MM 162, 181	BD INSULIN SYRINGE U-100 1 ML . 162, 181
AUM PEN NEEDLE 33G X 6 MM 162, 181	BD INSULIN SYRINGE U-500 162, 181
AUM READYGARD DUO PEN NEEDLE 32G X 4 MM..... 162, 181	BD INSULIN SYRINGE ULTRAFINE 29G X 1/2..... 162, 181
AUM SAFETY PEN NEEDLE 31G X 4 MM 162, 181	BD INSULIN SYRINGE ULTRAFINE 30G X 1/2..... 162, 181
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 90	BD INSULIN SYRINGE ULTRAFINE 31G X 5/16..... 162, 181
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG 90	BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM..... 162, 181
AUSTEDO XR PATIENT TITRATION . 90	BD PEN NEEDLE MINI U/F 31G X 5 MM 162, 181
AVMAPKI FAKZYNJA CO-PACK..... 39	BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM..... 162, 181
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT..... 182	BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM..... 162, 181
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT..... 182	BD PEN NEEDLE NANO U/F 32G X 4 MM 162, 181
AYVAKIT 38	BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM..... 162, 181
B	BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM..... 162, 181
BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG..... 119	BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM..... 163, 181
BD AUTOSHIELD 29G X 5MM... 162, 181	BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2..... 163, 181
BD AUTOSHIELD 29G X 8MM... 162, 181	BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16..... 163, 181
BD AUTOSHIELD DUO 30G X 5 MM 162, 181	
BD ECLIPSE SYRINGE 30G X 1/2 162, 181	
BD INSULIN SYR ULTRAFINE II 31G X 5/16 162, 181	
BD INSULIN SYRINGE 25G X 1. 162, 181	

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64.....	163, 181	CAREFINE PEN NEEDLES 29G X 12MM	163, 181
BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16.....	163, 181	CAREFINE PEN NEEDLES 30G X 8 MM	163, 181
BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8.....	163, 181	CAREFINE PEN NEEDLES 31G X 6 MM	163, 181
BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2.....	163, 181	CAREFINE PEN NEEDLES 31G X 8 MM	163, 181
BD SWAB SINGLE USE REGULAR PAD	163, 181	CAREFINE PEN NEEDLES 32G X 4 MM	163, 181
BD SWABS SINGLE USE BUTTERFLY PAD.....	163, 181	CAREFINE PEN NEEDLES 32G X 5 MM	163, 181
BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64.....	163, 181	CAREFINE PEN NEEDLES 32G X 6 MM	163, 181
BD VEO INSULIN SYR ULTRAFINE 31G X 15/64.....	163, 181	CAREONE INSULIN SYRINGE 30G X 1/2	163, 181
BD VEO INSULIN SYRINGE U/F 31G X 15/64	163, 181	CAREONE INSULIN SYRINGE 31G X 5/16	163, 181
BENDAMUSTINE HCL INTRAVENOUS SOLUTION.....	48	CARETOUCH ALCOHOL PREP PAD 70 %	163, 181
bendamustine hcl intravenous solution reconstituted.....	48	CARETOUCH INSULIN SYRINGE 28G X 5/16	163, 181
BENDEKA	48	CARETOUCH INSULIN SYRINGE 29G X 5/16	163, 181
BENLYSTA SUBCUTANEOUS.....	45	CARETOUCH INSULIN SYRINGE 30G X 5/16	163, 181
BESREMI	303	CARETOUCH INSULIN SYRINGE 31G X 5/16	163, 181
betaine	51	CARETOUCH PEN NEEDLES 29G X 12MM	163, 181
BETASERON SUBCUTANEOUS KIT	183	CARETOUCH PEN NEEDLES 31G X 5 MM	163, 181
bexarotene	55	CARETOUCH PEN NEEDLES 31G X 6 MM	164, 181
BIZENGRI (750 MG DOSE)	409	CARETOUCH PEN NEEDLES 31G X 8 MM	164, 181
bortezomib injection	57	CARETOUCH PEN NEEDLES 32G X 4 MM	164, 181
BORUZU	57	CARETOUCH PEN NEEDLES 32G X 5 MM	164, 181
bosentan	58	CARETOUCH PEN NEEDLES 33G X 4 MM	164, 181
BOSULIF ORAL CAPSULE 100 MG, 50 MG	59	carglumic acid oral tablet soluble	67
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	59	CAYSTON.....	43
BRAFTOVI ORAL CAPSULE 75 MG .	111	CIMZIA (2 SYRINGE)	69, 70
BRUKINSA	408		
C			
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG.....	63		
CALQUENCE	9		
CAPRELSA ORAL TABLET 100 MG, 300 MG	397		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

CIMZIA SUBCUTANEOUS KIT 2 X 200 MG 69, 70	COMFORT EZ PEN NEEDLES 32G X 6 MM 164, 181
CINQAIR..... 282, 283	COMFORT EZ PEN NEEDLES 32G X 8 MM 164, 181
CLEVER CHOICE COMFORT EZ 29G X 12MM 164, 181	COMFORT EZ PEN NEEDLES 33G X 4 MM 164, 181
CLEVER CHOICE COMFORT EZ 33G X 4 MM 164, 181	COMFORT EZ PEN NEEDLES 33G X 5 MM 164, 181
CLICKFINE PEN NEEDLES 31G X 6 MM 164, 181	COMFORT EZ PEN NEEDLES 33G X 6 MM 164, 181
CLICKFINE PEN NEEDLES 31G X 8 MM 164, 181	COMFORT EZ PEN NEEDLES 33G X 8 MM 164, 181
CLICKFINE PEN NEEDLES 32G X 4 MM 164, 181	COMFORT EZ PRO PEN NEEDLES 30G X 8 MM..... 164, 181
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG 62	COMFORT EZ PRO PEN NEEDLES 31G X 4 MM..... 164, 181
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG 62	COMFORT EZ PRO PEN NEEDLES 31G X 5 MM..... 165, 181
COMETRIQ (60 MG DAILY DOSE)..... 62	COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM..... 165, 181
COMFORT ASSIST INSULIN SYRINGE 29G X 1/2..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM..... 165, 181
COMFORT ASSIST INSULIN SYRINGE 31G X 5/16..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 28G X 1/2..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 29G X 1/2..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 30G X 1/2..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 30G X 5/16..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 31G X 15/64..... 164, 181	COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM..... 165, 181
COMFORT EZ INSULIN SYRINGE 31G X 5/16..... 164, 181	COPIKTRA..... 101
COMFORT EZ PEN NEEDLES 31G X 5 MM 164, 181	CORTROPHIN 75, 76
COMFORT EZ PEN NEEDLES 31G X 6 MM 164, 181	COSENTYX (300 MG DOSE)..... 309, 310
COMFORT EZ PEN NEEDLES 31G X 8 MM 164, 181	COSENTYX INTRAVENOUS..... 307, 308
COMFORT EZ PEN NEEDLES 32G X 4 MM 164, 181	COSENTYX SENSOREADY (300 MG) 309, 310
COMFORT EZ PEN NEEDLES 32G X 5 MM 164, 181	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML 309, 310
COMFORT EZ PEN NEEDLES 32G X 6 MM 164, 181	COSENTYX UNOREADY 309, 310
COMFORT EZ PEN NEEDLES 32G X 8 MM 164, 181	COTELLIC 74

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

CURITY ALCOHOL PREPS PAD 70 %
 165, 181
 CURITY ALL PURPOSE SPONGES PAD
 2..... 165, 181
 CURITY GAUZE PAD 2 165, 181
 CURITY GAUZE SPONGE PAD 2..... 165,
 181
 CURITY SPONGES PAD 2 165, 181
 CVS GAUZE PAD 2 165, 181
 CVS GAUZE STERILE PAD 2 165, 181
 CYLTEZO (2 PEN) 17, 19
 CYLTEZO (2 SYRINGE) 17, 19
 CYLTEZO-CD/UC/HS STARTER.... 17, 19
 CYLTEZO-PSORIASIS/UV STARTER 17,
 19
D
 dalfampridine er 82
 DANYELZA 228
 DANZITEN 231
 dasatinib oral tablet 100 mg, 140 mg, 20 mg,
 50 mg, 70 mg, 80 mg 84
 DATROWAY 85
 DAURISMO ORAL TABLET 100 MG, 25
 MG 143
 deferasirox granules 87, 88
 deferasirox oral tablet 87, 88
 DERMACEA GAUZE SPONGE PAD 2
 165, 181
 DERMACEA IV DRAIN SPONGES PAD
 2..... 165, 181
 DERMACEA NON-WOVEN SPONGES
 PAD 2..... 165, 181
 DERMACEA TYPE VII GAUZE PAD 2
 165, 181
 DIACOMIT ORAL CAPSULE 250 MG,
 500 MG 332
 DIACOMIT ORAL PACKET 250 MG, 500
 MG 332
 DIATHRIVE PEN NEEDLE 31G X 5 MM
 165, 181
 DIATHRIVE PEN NEEDLE 31G X 6 MM
 165, 181
 DIATHRIVE PEN NEEDLE 31G X 8 MM
 165, 181

DIATHRIVE PEN NEEDLE 32G X 4 MM
 165, 181
 diclofenac epolamine external 92
 diclofenac sodium external solution 2 %.. 91
 dimethyl fumarate oral capsule delayed
 release 120 mg, 240 mg 93
 dimethyl fumarate starter pack oral capsule
 delayed release therapy pack 93
 dronabinol 96
 DROPLET INSULIN SYRINGE 29G X 1/2
 165, 181
 DROPLET INSULIN SYRINGE 30G X 1/2
 165, 181
 DROPLET INSULIN SYRINGE 30G X
 15/64 165, 181
 DROPLET INSULIN SYRINGE 30G X
 5/16 165, 181
 DROPLET INSULIN SYRINGE 31G X 1/4
 165, 181
 DROPLET INSULIN SYRINGE 31G X
 15/64 165, 181
 DROPLET INSULIN SYRINGE 31G X
 5/16 165, 181
 DROPLET MICRON 34G X 3.5 MM... 166,
 181
 DROPLET PEN NEEDLES 29G X 10MM
 166, 181
 DROPLET PEN NEEDLES 29G X 12MM
 166, 181
 DROPLET PEN NEEDLES 30G X 8 MM
 166, 181
 DROPLET PEN NEEDLES 31G X 5 MM
 166, 181
 DROPLET PEN NEEDLES 31G X 6 MM
 166, 181
 DROPLET PEN NEEDLES 31G X 8 MM
 166, 181
 DROPLET PEN NEEDLES 32G X 4 MM
 166, 181
 DROPLET PEN NEEDLES 32G X 5 MM
 166, 181
 DROPLET PEN NEEDLES 32G X 6 MM
 166, 181
 DROPLET PEN NEEDLES 32G X 8 MM
 166, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

DROPSAFE ALCOHOL PREP PAD 70 %
 166, 181
 DROPSAFE SAFETY PEN NEEDLES 31G
 X 5 MM..... 166, 181
 DROPSAFE SAFETY PEN NEEDLES 31G
 X 6 MM..... 166, 181
 DROPSAFE SAFETY PEN NEEDLES 31G
 X 8 MM..... 166, 181
 DROPSAFE SAFETY SYRINGE/NEEDLE
 29G X 1/2..... 166, 181
 DROPSAFE SAFETY SYRINGE/NEEDLE
 31G X 15/64..... 166, 181
 DROPSAFE SAFETY SYRINGE/NEEDLE
 31G X 5/16..... 166, 181
 droxidopa 97
 DRUG MART ULTRA COMFORT SYR
 29G X 1/2..... 166, 181
 DRUG MART ULTRA COMFORT SYR
 30G X 5/16..... 166, 181
 DRUG MART UNIFINE PENTIPS 31G X
 5 MM 166, 181
 DUPIXENT SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR .. 98, 100
 DUPIXENT SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE . 98,
 100

E

EASY COMFORT ALCOHOL PADS PAD
 166, 181
 EASY COMFORT INSULIN SYRINGE
 29G X 5/16..... 166, 181
 EASY COMFORT INSULIN SYRINGE
 30G X 1/2..... 166, 181
 EASY COMFORT INSULIN SYRINGE
 30G X 5/16..... 166, 181
 EASY COMFORT INSULIN SYRINGE
 31G X 1/2..... 166, 181
 EASY COMFORT INSULIN SYRINGE
 31G X 5/16..... 166, 181
 EASY COMFORT INSULIN SYRINGE
 32G X 5/16..... 166, 181
 EASY COMFORT PEN NEEDLES 29G X
 4MM 166, 181
 EASY COMFORT PEN NEEDLES 29G X
 5MM 166, 181

EASY COMFORT PEN NEEDLES 31G X
 5 MM 166, 181
 EASY COMFORT PEN NEEDLES 31G X
 6 MM 166, 181
 EASY COMFORT PEN NEEDLES 31G X
 8 MM 166, 181
 EASY COMFORT PEN NEEDLES 32G X
 4 MM 167, 181
 EASY COMFORT PEN NEEDLES 33G X
 4 MM 167, 181
 EASY COMFORT PEN NEEDLES 33G X
 5 MM 167, 181
 EASY COMFORT PEN NEEDLES 33G X
 6 MM 167, 181
 EASY GLIDE PEN NEEDLES 33G X 4
 MM 167, 181
 EASY TOUCH ALCOHOL PREP
 MEDIUM PAD 70 %..... 167, 181
 EASY TOUCH FLIPLOCK INSULIN SY
 29G X 1/2..... 167, 181
 EASY TOUCH FLIPLOCK INSULIN SY
 30G X 1/2..... 167, 181
 EASY TOUCH FLIPLOCK INSULIN SY
 30G X 5/16..... 167, 181
 EASY TOUCH FLIPLOCK INSULIN SY
 31G X 5/16..... 167, 181
 EASY TOUCH FLIPLOCK SAFETY SYR
 27G X 1/2..... 167, 181
 EASY TOUCH INSULIN BARRELS U-
 100 1 ML..... 167, 181
 EASY TOUCH INSULIN SAFETY SYR
 29G X 1/2..... 167, 181
 EASY TOUCH INSULIN SAFETY SYR
 30G X 1/2..... 167, 181
 EASY TOUCH INSULIN SAFETY SYR
 30G X 5/16..... 167, 181
 EASY TOUCH INSULIN SYRINGE 27G
 X 1/2..... 167, 181
 EASY TOUCH INSULIN SYRINGE 27G
 X 5/8..... 167, 181
 EASY TOUCH INSULIN SYRINGE 28G
 X 1/2..... 167, 181
 EASY TOUCH INSULIN SYRINGE 29G
 X 1/2..... 167, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

EASY TOUCH INSULIN SYRINGE 30G X 1/2.....	167, 181	EMBECTA AUTOSHIELD DUO 30G X 5 MM	168, 181
EASY TOUCH INSULIN SYRINGE 30G X 5/16.....	167, 181	EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64	168, 181
EASY TOUCH INSULIN SYRINGE 31G X 5/16.....	167, 181	EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16	168, 181
EASY TOUCH PEN NEEDLES 29G X 12MM	167, 181	EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2.....	168, 181
EASY TOUCH PEN NEEDLES 30G X 5 MM	167, 181	EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16.....	168, 181
EASY TOUCH PEN NEEDLES 30G X 6 MM	167, 181	EMBECTA INSULIN SYRINGE 28G X 1/2	168, 181
EASY TOUCH PEN NEEDLES 30G X 8 MM	167, 181	EMBECTA INSULIN SYRINGE U-100 27G X 5/8.....	168, 181
EASY TOUCH PEN NEEDLES 31G X 5 MM	167, 181	EMBECTA INSULIN SYRINGE U-100 28G X 1/2.....	168, 181
EASY TOUCH PEN NEEDLES 31G X 6 MM	167, 181	EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM.....	168, 181
EASY TOUCH PEN NEEDLES 31G X 8 MM	167, 181	EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM.....	168, 181
EASY TOUCH PEN NEEDLES 32G X 4 MM	167, 181	EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM.....	168, 181
EASY TOUCH PEN NEEDLES 32G X 5 MM	167, 181	EMBRACE PEN NEEDLES 29G X 12MM	168, 181
EASY TOUCH PEN NEEDLES 32G X 6 MM	167, 181	EMBRACE PEN NEEDLES 30G X 5 MM	168, 181
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	168, 181	EMBRACE PEN NEEDLES 30G X 8 MM	168, 181
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	168, 181	EMBRACE PEN NEEDLES 31G X 5 MM	168, 181
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	168, 181	EMBRACE PEN NEEDLES 31G X 6 MM	168, 181
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	168, 181	EMBRACE PEN NEEDLES 31G X 8 MM	168, 181
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	168, 181	EMBRACE PEN NEEDLES 32G X 4 MM	168, 181
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	168, 181	EMGALITY.....	139
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	168, 181	EMGALITY (300 MG DOSE)	139
ELAHERE	224	EMRELIS	342
ELIGARD	200	ENBREL MINI.....	123, 124
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML	106	ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML	123, 124
		ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	123, 124

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

ENBREL SUBCUTANEOUS SOLUTION
RECONSTITUTED..... 123, 124

ENBREL SURECLICK SUBCUTANEOUS
SOLUTION AUTO-INJECTOR 123, 124

EPCLUSA ORAL PACKET 150-37.5 MG,
200-50 MG..... 321

EPCLUSA ORAL TABLET..... 321

EPIDIOLEX..... 64

EPKINLY 116

EQL ALCOHOL SWABS PAD 70 %... 168,
181

EQL GAUZE PAD 2 168, 181

EQL INSULIN SYRINGE 30G X 5/16. 168,
181

ERBITUX 71

ERIVEDGE..... 404

ERLEADA ORAL TABLET 240 MG, 60
MG 27

erlotinib hcl oral tablet 100 mg, 150 mg, 25
mg 121

everolimus oral tablet 10 mg, 2.5 mg, 5 mg,
7.5 mg 125

everolimus oral tablet soluble 126

EXEL COMFORT POINT PEN NEEDLE
29G X 12MM..... 168, 181

F

FASENRA 49, 50

FASENRA PEN..... 49, 50

fentanyl citrate buccal lozenge on a handle
..... 130

FIFTY50 PEN NEEDLES 32G X 6 MM
..... 168, 181

fingolimod hcl..... 134

FINTEPLA..... 129

FOTIVDA 353

FREESTYLE PRECISION INS SYR 30G X
5/16 168, 181

FREESTYLE PRECISION INS SYR 31G X
5/16 168, 181

FRUZAQLA ORAL CAPSULE 1 MG, 5
MG 137

FYARRO 318

G

GAUZE PADS PAD 2..... 168, 181

GAUZE TYPE VII MEDI-PAK PAD 2 168,
181

GAVRETO 275

gefitinib 141

GILOTRIF 20

glatiramer acetate subcutaneous solution
prefilled syringe 20 mg/ml, 40 mg/ml 144

glatopa subcutaneous solution prefilled
syringe 20 mg/ml, 40 mg/ml 144

GLOBAL ALCOHOL PREP EASE 168, 181

GLOBAL EASE INJECT PEN NEEDLES
29G X 12MM..... 168, 181

GLOBAL EASE INJECT PEN NEEDLES
31G X 5 MM..... 168, 181

GLOBAL EASE INJECT PEN NEEDLES
31G X 8 MM..... 169, 181

GLOBAL EASE INJECT PEN NEEDLES
32G X 4 MM..... 169, 181

GLOBAL EASY GLIDE INSULIN SYR
31G X 15/64..... 169, 181

GLOBAL INJECT EASE INSULIN SYR
28G X 1/2..... 169, 181

GLOBAL INJECT EASE INSULIN SYR
29G X 1/2..... 169, 181

GLOBAL INJECT EASE INSULIN SYR
30G X 1/2..... 169, 181

GLOBAL INJECT EASE INSULIN SYR
30G X 5/16..... 169, 181

GLUCOPRO INSULIN SYRINGE 30G X
1/2 169, 181

GLUCOPRO INSULIN SYRINGE 30G X
5/16 169, 181

GLUCOPRO INSULIN SYRINGE 31G X
5/16 169, 181

GNP ALCOHOL SWABS PAD.... 169, 181

GNP INSULIN SYRINGE 28G X 1/2 .. 169,
181

GNP INSULIN SYRINGE 29G X 1/2 .. 169,
181

GNP INSULIN SYRINGE 30G X 5/16 169,
181

GNP INSULIN SYRINGES 29GX1/2 .. 169,
181

GNP INSULIN SYRINGES 30G X 5/16
..... 169, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

GNP INSULIN SYRINGES 30GX5/16 169, 181
 GNP INSULIN SYRINGES 31GX5/16 169, 181
 GNP STERILE GAUZE PAD 2 169, 181
 GNP ULTRA COM INSULIN SYRINGE
 30G X 5/16..... 169, 181
 GOMEKLI ORAL CAPSULE 1 MG, 2 MG
 223
 GOMEKLI ORAL TABLET SOLUBLE223
 GOODSENSE ALCOHOL SWABS PAD
 70 % 169, 181

H
 HAEGARDA SUBCUTANEOUS
 SOLUTION RECONSTITUTED 2000
 UNIT, 3000 UNIT 61
 HARVONI ORAL PACKET 33.75-150
 MG, 45-200 MG 194
 HARVONI ORAL TABLET 194
 HEALTHWISE INSULIN SYR/NEEDLE
 30G X 5/16..... 169, 170, 181
 HEALTHWISE INSULIN SYR/NEEDLE
 31G X 5/16..... 170, 181
 HEALTHWISE MICRON PEN NEEDLES
 32G X 4 MM..... 170, 181
 HEALTHWISE SHORT PEN NEEDLES
 31G X 5 MM..... 170, 181
 HEALTHWISE SHORT PEN NEEDLES
 31G X 8 MM..... 170, 181
 HEALTHY ACCENTS UNIFINE PENTIP
 29G X 12MM..... 170, 181
 HEALTHY ACCENTS UNIFINE PENTIP
 31G X 5 MM..... 170, 181
 HEALTHY ACCENTS UNIFINE PENTIP
 31G X 6 MM..... 170, 181
 HEALTHY ACCENTS UNIFINE PENTIP
 31G X 8 MM..... 170, 181
 HEALTHY ACCENTS UNIFINE PENTIP
 32G X 4 MM..... 170, 181
 H-E-B INCONTROL ALCOHOL PAD 169,
 181
 H-E-B INCONTROL PEN NEEDLES 29G
 X 12MM..... 169, 181
 H-E-B INCONTROL PEN NEEDLES 31G
 X 5 MM..... 169, 181

H-E-B INCONTROL PEN NEEDLES 31G
 X 6 MM..... 169, 181
 H-E-B INCONTROL PEN NEEDLES 31G
 X 8 MM..... 169, 181
 H-E-B INCONTROL PEN NEEDLES 32G
 X 4 MM..... 169, 181
 HERCEPTIN HYLECTA..... 372
 HERZUMA..... 373
 HM STERILE ALCOHOL PREP PAD 170,
 181
 HM STERILE PADS PAD 2..... 170, 181
 HM ULTICARE INSULIN SYRINGE 30G
 X 1/2..... 170, 181
 HM ULTICARE INSULIN SYRINGE 31G
 X 5/16..... 170, 181
 HM ULTICARE SHORT PEN NEEDLES
 31G X 8 MM..... 170, 181
 HUMIRA (2 PEN) SUBCUTANEOUS
 AUTO-INJECTOR KIT..... 11, 12, 13
 HUMIRA (2 SYRINGE)
 SUBCUTANEOUS PREFILLED
 SYRINGE KIT 10 MG/0.1ML, 20
 MG/0.2ML, 40 MG/0.4ML, 40
 MG/0.8ML 11, 12, 13
 HUMIRA-CD/UC/HS STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 11, 12, 13
 HUMIRA-PED<40KG CROHNS
 STARTER..... 11, 12, 13
 HUMIRA-PED>=40KG CROHNS START
 11, 12, 13
 HUMIRA-PED>=40KG UC STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 11, 12, 13
 HUMIRA-PS/UV/ADOL HS STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 11, 12, 13
 HUMIRA-PSORIASIS/UEIT STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 11, 12, 13

I
 IBRANCE 255
 icatibant acetate..... 152
 ICLUSIG 273
 IDHIFA 110

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

imatinib mesylate oral tablet 100 mg, 400 mg	154	INSUPEN PEN NEEDLES 31G X 8 MM	170, 181
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG	151	INSUPEN PEN NEEDLES 32G X 4 MM	170, 181
IMBRUVICA ORAL SUSPENSION.....	151	INSUPEN PEN NEEDLES 33G X 4 MM	170, 181
IMBRUVICA ORAL TABLET	151	INSUPEN SENSITIVE 32G X 6 MM... 170, 181	
IMDELLTRA	338	INSUPEN SENSITIVE 32G X 8 MM... 170, 181	
IMJUDO	376	INSUPEN ULTRAFIN 29G X 12MM.. 170, 181	
IMKELDI.....	155	INSUPEN ULTRAFIN 30G X 8 MM... 170, 181	
IMPAVIDO.....	222	INSUPEN ULTRAFIN 31G X 6 MM... 170, 181	
INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM.....	170, 181	INSUPEN ULTRAFIN 31G X 8 MM... 170, 181	
INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM.....	170, 181	ITOVEBI ORAL TABLET 3 MG, 9 MG	157
INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM.....	170, 181	IWILFIN	102
INCRELEX.....	216	J	
infliximab.....	158, 159, 160	J & J GAUZE PAD 2.....	170, 181
INGREZZA ORAL CAPSULE.....	396	JAKAFI.....	305
INGREZZA ORAL CAPSULE SPRINKLE	396	javygtor oral tablet	306
INGREZZA ORAL CAPSULE THERAPY PACK.....	396	JAYPIRCA ORAL TABLET 100 MG, 50 MG	271
INLYTA ORAL TABLET 1 MG, 5 MG..	41	JEMPERLI.....	95
INQOVI	86	K	
INREBIC.....	128	KALYDECO.....	187
INSULIN SYRINGE 29G X 1/2	170, 181	KENDALL HYDROPHILIC FOAM DRESS PAD 2	170, 181
INSULIN SYRINGE 30G X 5/16 ..	170, 181	KENDALL HYDROPHILIC FOAM PLUS PAD 2.....	170, 181
INSULIN SYRINGE 31G X 5/16 ..	170, 181	KERENDIA	133
INSULIN SYRINGE/NEEDLE 27G X 1/2	170, 181	KESIMPTA.....	244
INSULIN SYRINGE/NEEDLE 28G X 1/2	170, 181	KEYTRUDA INTRAVENOUS SOLUTION.....	263
INSULIN SYRINGE-NEEDLE U-100 27G X 1/2.....	170, 181	KIMMTRAK	340
INSULIN SYRINGE-NEEDLE U-100 28G X 1/2.....	170, 181	KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	25, 26
INSULIN SYRINGE-NEEDLE U-100 30G X 5/16.....	170, 181	KINRAY INSULIN SYRINGE 29G X 1/2	171, 181
INSULIN SYRINGE-NEEDLE U-100 31G X 1/4.....	170, 181	KISQALI (200 MG DOSE).....	286
INSULIN SYRINGE-NEEDLE U-100 31G X 5/16.....	170, 181	KISQALI (400 MG DOSE).....	286
INSUPEN PEN NEEDLES 31G X 5 MM	170, 181		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

KISQALI (600 MG DOSE)	286	lidocaine external patch 5 %	207
KISQALI FEMARA (200 MG DOSE) ..	287	lidocaine-prilocaine external cream	208
KISQALI FEMARA (400 MG DOSE) ..	287	lidocan	207
KISQALI FEMARA (600 MG DOSE) ..	287	LITETOUCH INSULIN SYRINGE 28G X	
KMART VALU INSULIN SYRINGE 29G		1/2	171, 181
U-100 1 ML	171, 181	LITETOUCH INSULIN SYRINGE 29G X	
KMART VALU INSULIN SYRINGE 30G		1/2	171, 181
U-100 0.3 ML	171, 181	LITETOUCH INSULIN SYRINGE 30G X	
KMART VALU INSULIN SYRINGE 30G		5/16	171, 181
U-100 1 ML	171, 181	LITETOUCH INSULIN SYRINGE 31G X	
KOSELUGO ORAL CAPSULE 10 MG, 25		5/16	171, 181
MG	314	LITETOUCH PEN NEEDLES 29G X	
KRAZATI	10	12.7MM	171, 181
KROGER PEN NEEDLES 29G X 12MM		LITETOUCH PEN NEEDLES 31G X 5	
.....	171, 181	MM	171, 181
KROGER PEN NEEDLES 31G X 8 MM		LITETOUCH PEN NEEDLES 31G X 6	
.....	171, 181	MM	171, 181
KYNMOBI	29	LITETOUCH PEN NEEDLES 31G X 8	
KYNMOBI TITRATION KIT	29	MM	171, 181
L		LITETOUCH PEN NEEDLES 32G X 4	
LANREOTIDE ACETATE	190	MM	171, 181
lapatinib ditosylate	191	LIVTENCITY	215
LAZCLUZE ORAL TABLET 240 MG, 80		LONSURF ORAL TABLET 15-6.14 MG,	
MG	193	20-8.19 MG	378
LEADER UNIFINE PENTIPS 31G X 5		LOQTORZI	365
MM	171, 181	LORBRENA ORAL TABLET 100 MG, 25	
LEADER UNIFINE PENTIPS 32G X 4		MG	210
MM	171, 181	LUMAKRAS ORAL TABLET 120 MG,	
LEADER UNIFINE PENTIPS PLUS 31G		240 MG, 320 MG	331
X 5 MM	171, 181	LUNSUMIO	226
LEADER UNIFINE PENTIPS PLUS 31G		LUPRON DEPOT (1-MONTH)	201, 202
X 8 MM	171, 181	LUPRON DEPOT (3-MONTH)	201, 202
lenalidomide	195	LUPRON DEPOT (4-MONTH)	201, 202
LENVIMA (10 MG DAILY DOSE)	196	LUPRON DEPOT (6-MONTH)	201, 202
LENVIMA (12 MG DAILY DOSE)	196	LUPRON DEPOT-PED (3-MONTH) ...	203,
LENVIMA (14 MG DAILY DOSE)	196	204	
LENVIMA (18 MG DAILY DOSE)	196	LUPRON DEPOT-PED (6-MONTH) ...	203,
LENVIMA (20 MG DAILY DOSE)	196	204	
LENVIMA (24 MG DAILY DOSE)	196	LUTRATE DEPOT	199
LENVIMA (4 MG DAILY DOSE)	196	LYBALVI	245
LENVIMA (8 MG DAILY DOSE)	196	LYNPARZA ORAL TABLET	246
LEUPROLIDE ACETATE (3 MONTH) 199		LYTGOBI (12 MG DAILY DOSE)	138
leuprolide acetate injection	198	LYTGOBI (16 MG DAILY DOSE)	138
l-glutamine oral packet	205	LYTGOBI (20 MG DAILY DOSE)	138
lidocaine external ointment 5 %	206		

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

M

MAGELLAN INSULIN SAFETY SYR 29G X 1/2.....	171, 181	MEKTOVI.....	56
MAGELLAN INSULIN SAFETY SYR 30G X 5/16.....	171, 181	MICRODOT PEN NEEDLE 31G X 6 MM	172, 181
MARGENZA.....	214	MICRODOT PEN NEEDLE 32G X 4 MM	172, 181
MAVENCLAD (10 TABS).....	72	MICRODOT PEN NEEDLE 33G X 4 MM	172, 181
MAVENCLAD (4 TABS).....	72	mifepristone oral tablet 300 mg.....	221
MAVENCLAD (5 TABS).....	72	MIPLYFFA.....	32
MAVENCLAD (6 TABS).....	72	MIRASORB SPONGES 2.....	172, 181
MAVENCLAD (7 TABS).....	72	MM PEN NEEDLES 32G X 4 MM	172, 181
MAVENCLAD (8 TABS).....	72	modafinil oral tablet 100 mg, 200 mg.....	227
MAVENCLAD (9 TABS).....	72	MONOJECT INSULIN SYRINGE 25G X 5/8.....	172, 181
MAXICOMFORT II PEN NEEDLE 31G X 6 MM.....	171, 181	MONOJECT INSULIN SYRINGE 27G X 1/2.....	172, 181
MAXI-COMFORT INSULIN SYRINGE 28G X 1/2.....	171, 181	MONOJECT INSULIN SYRINGE 28G X 1/2.....	172, 181
MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM.....	171, 181	MONOJECT INSULIN SYRINGE 29G X 1/2.....	172, 181
MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM.....	171, 181	MONOJECT INSULIN SYRINGE 30G X 5/16.....	172, 181
MAXICOMFORT SYR 27G X 1/2	171, 181	MONOJECT INSULIN SYRINGE 31G X 5/16.....	172, 181
MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG.....	317	MONOJECT INSULIN SYRINGE U-100 1 ML.....	172, 181
MAYZENT STARTER PACK.....	317	MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2.....	172, 181
MEDIC INSULIN SYRINGE 30G X 5/16	171, 181	MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2.....	172, 181
MEDICINE SHOPPE PEN NEEDLES 29G X 12MM.....	171, 181	MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16.....	172, 181
MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM.....	171, 181	MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	147
MEDPURA ALCOHOL PADS 70 % EXTERNAL.....	172, 181	MVASI.....	53
MEIJER ALCOHOL SWABS PAD 70 %	172, 181	N	
MEIJER PEN NEEDLES 29G X 12MM	172, 181	NATPARA.....	256
MEIJER PEN NEEDLES 31G X 6 MM	172, 181	NERLYNX.....	229
MEIJER PEN NEEDLES 31G X 8 MM	172, 181	NEULASTA ONPRO.....	260
MEKINIST ORAL SOLUTION RECONSTITUTED.....	368	NIKTIMVO.....	40
MEKINIST ORAL TABLET 0.5 MG, 2 MG.....	369	NINLARO.....	189
		nitisinone.....	237
		NIVESTYM.....	132

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR..... 324, 325

NOVOFINE AUTOCOVER 30G X 8 MM
..... 172, 181

NOVOFINE PEN NEEDLE 32G X 6 MM
..... 172, 181

NOVOFINE PLUS PEN NEEDLE 32G X 4
MM 172, 181

NOVOTWIST PEN NEEDLE 32G X 5 MM
..... 172, 181

NUBEQA..... 83

NUCALA SUBCUTANEOUS SOLUTION
AUTO-INJECTOR 218, 219

NUCALA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 100 MG/ML, 40
MG/0.4ML 218, 219

NUCALA SUBCUTANEOUS SOLUTION
RECONSTITUTED..... 218, 219

NUPLAZID ORAL CAPSULE..... 268

NUPLAZID ORAL TABLET 10 MG.... 268

NURTEC..... 292, 293

NYVEPRIA 259

O

OCREVUS..... 242

OCREVUS ZUNOVO 243

ODOMZO 328

OFEV 232, 233

OGIVRI..... 370

OGSIVEO ORAL TABLET 100 MG, 150
MG, 50 MG..... 236

OJEMDA ORAL SUSPENSION
RECONSTITUTED..... 366

OJEMDA ORAL TABLET 366

OJJAARA 225

ONAPGO 28

ONTRUZANT 371

ONUREG 42

OPDIVO 238

OPDIVO QVANTIG 239

OPDUALAG..... 240

OPSUMIT 213

ORENCIA CLICKJECT..... 4, 5

ORENCIA INTRAVENOUS 2, 3

ORENCIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 4, 5

ORFADIN ORAL SUSPENSION..... 237

ORGOVYX..... 280

ORILISSA ORAL TABLET 150 MG, 200
MG 104, 105

ORKAMBI ORAL TABLET 212

ORSERDU ORAL TABLET 345 MG, 86
MG 103

OTEZLA..... 30, 31

oxandrolone oral 253

OZEMPIC (0.25 OR 0.5 MG/DOSE)..... 146

OZEMPIC (1 MG/DOSE) 146

OZEMPIC (2 MG/DOSE) 146

P

pazopanib hcl 258

PC UNIFINE PENTIPS 31G X 5 MM.. 172,
181

PC UNIFINE PENTIPS 31G X 6 MM.. 172,
181

PC UNIFINE PENTIPS 31G X 8 MM.. 172,
181

PEGASYS SUBCUTANEOUS SOLUTION
180 MCG/ML 261

PEGASYS SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 261

PEMAZYRE..... 264

PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
..... 172, 181

PEN NEEDLES 30G X 5 MM (OTC)... 172,
181

PEN NEEDLES 30G X 8 MM 172, 181

PEN NEEDLES 32G X 4 MM (OTC)... 172,
181

PEN NEEDLES 32G X 5 MM 172, 181

penicillamine oral tablet..... 265, 266

PENTIPS 29G X 12MM (RX)..... 172, 181

PENTIPS 31G X 5 MM (RX)..... 172, 181

PENTIPS 31G X 8 MM (RX)..... 172, 181

PENTIPS 32G X 4 MM (RX)..... 172, 181

PENTIPS GENERIC PEN NEEDLES 29G
X 12MM..... 172, 181

PENTIPS GENERIC PEN NEEDLES 31G
X 6 MM..... 172, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

PENTIPS GENERIC PEN NEEDLES 32G X 6 MM.....	172, 181	PREVENT SAFETY PEN NEEDLES 31G X 8 MM.....	173, 181
PIP PEN NEEDLES 31G X 5MM 31G X 5 MM	172, 181	PREVYMIS ORAL TABLET	197
PIP PEN NEEDLES 32G X 4MM 32G X 4 MM	173, 181	PRO COMFORT ALCOHOL PAD 70 %	173, 181
PIQRAY (200 MG DAILY DOSE).....	22	PRO COMFORT INSULIN SYRINGE 30G X 1/2.....	173, 181
PIQRAY (250 MG DAILY DOSE).....	22	PRO COMFORT INSULIN SYRINGE 30G X 5/16.....	173, 181
PIQRAY (300 MG DAILY DOSE).....	22	PRO COMFORT INSULIN SYRINGE 31G X 5/16.....	173, 181
pirfenidone oral capsule.....	269, 270	PRO COMFORT PEN NEEDLES 31G X 8 MM	173, 181
pirfenidone oral tablet 267 mg, 534 mg, 801 mg	269, 270	PRO COMFORT PEN NEEDLES 32G X 4 MM	173, 181
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	184	PRO COMFORT PEN NEEDLES 32G X 5 MM	173, 181
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	184	PRO COMFORT PEN NEEDLES 32G X 6 MM	173, 181
PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR	184	PRODIGY INSULIN SYRINGE 28G X 1/2	173, 181
PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	184	PRODIGY INSULIN SYRINGE 31G X 5/16	173, 181
POMALYST	272	PROMACTA ORAL PACKET 12.5 MG, 25 MG	108, 109
posaconazole oral tablet delayed release	274	PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG	108, 109
PRECISION SUREDOSE PLUS SYR 29G X 1/2.....	173, 181	PURE COMFORT ALCOHOL PREP PAD	173, 181
PRECISION SURE-DOSE SYRINGE 28G X 1/2.....	173, 181	PURE COMFORT PEN NEEDLE 32G X 4 MM	173, 181
PRECISION SURE-DOSE SYRINGE 29G X 1/2.....	173, 181	PURE COMFORT PEN NEEDLE 32G X 5 MM	173, 181
PRECISION SURE-DOSE SYRINGE 30G X 3/8.....	173, 181	PURE COMFORT PEN NEEDLE 32G X 6 MM	173, 181
PRECISION SURE-DOSE SYRINGE 30G X 5/16.....	173, 181	PURE COMFORT PEN NEEDLE 32G X 8 MM	173, 181
PREFERRED PLUS INSULIN SYRINGE 28G X 1/2.....	173, 181	PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM.....	173, 181
PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM.....	173, 181	PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM.....	173, 181
PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM.....	173, 181	PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM.....	173, 181
PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM.....	173, 181	PX SHORTLENGTH PEN NEEDLES 31G X 8 MM.....	173, 181
PREVENT SAFETY PEN NEEDLES 31G X 6 MM.....	173, 181		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

pyrimethamine oral 276

Q

QC ALCOHOL 173, 181

QC ALCOHOL SWABS PAD 70 %..... 173, 181

QC BORDER ISLAND GAUZE PAD 2 173, 181

QINLOCK..... 296

QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM..... 173, 181

QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM..... 173, 181

QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM..... 173, 181

QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM..... 174, 181

QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM..... 174, 181

quinine sulfate oral..... 277

QULIPTA 36

R

RA ALCOHOL SWABS PAD 70 %..... 174, 181

RA INSULIN SYRINGE 29G X 1/2..... 174, 181

RA INSULIN SYRINGE 30G X 5/16... 174, 181

ra isopropyl alcohol wipes 174, 181

RA PEN NEEDLES 31G X 5 MM. 174, 181

RA PEN NEEDLES 31G X 8 MM. 174, 181

RA STERILE PAD 2 174, 181

RALDESY 375

RAYA SURE PEN NEEDLE 29G X 12MM 174, 181

RAYA SURE PEN NEEDLE 31G X 4 MM 174, 181

RAYA SURE PEN NEEDLE 31G X 5 MM 174, 181

RAYA SURE PEN NEEDLE 31G X 6 MM 174, 181

REALITY INSULIN SYRINGE 28G X 1/2 174, 181

REALITY INSULIN SYRINGE 29G X 1/2 174, 181

REALITY SWABS PAD..... 174, 181

RELION ALCOHOL SWABS PAD 174, 181

RELI-ON INSULIN SYRINGE 29G 0.3 ML..... 174, 181

RELI-ON INSULIN SYRINGE 29G 0.5 ML..... 174, 181

RELI-ON INSULIN SYRINGE 29G X 1/2 174, 181

RELION INSULIN SYRINGE 31G X 15/64 174, 181

RELION MINI PEN NEEDLES 31G X 6 MM 174, 181

RELION PEN NEEDLES 31G X 6 MM174, 181

RELION PEN NEEDLES 31G X 8 MM174, 181

RESTORE CONTACT LAYER PAD 2 174, 181

RETACRIT INJECTION SOLUTION

10000 UNIT/ML, 10000

UNIT/ML(1ML), 2000 UNIT/ML, 20000

UNIT/ML, 3000 UNIT/ML, 4000

UNIT/ML, 40000 UNIT/ML 117, 118

RETEVMO ORAL CAPSULE 40 MG, 80 MG 313

RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 313

REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG..... 285

REZLIDHIA 247

REZUROCK..... 46

RIABNI..... 301

RINVOQ 382, 384

RINVOQ LQ..... 382, 384

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

RITUXAN HYCELA	299	SKYRIZI (150 MG DOSE)	297, 298
ROMVIMZA	403	SKYRIZI PEN	297, 298
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG	112	SM ALCOHOL PREP PAD	175, 181
ROZLYTREK ORAL PACKET	113	SM ALCOHOL PREP PAD 6-70 % EXTERNAL	175, 181
RUBRACA	304	SM ALCOHOL PREP PAD 70 %..	175, 181
RUXIENCE	302	SM GAUZE PAD 2	175, 181
RYBELSUS	146	sodium oxybate	319, 320
RYBELSUS (FORMULATION R2).....	146	SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML	190
RYBREVANT	24	SOMAVERT.....	262
RYDAPT.....	220	sorafenib tosylate	329
RYTELO.....	156	SPRAVATO (56 MG DOSE).....	122
S		SPRAVATO (84 MG DOSE).....	122
SAFETY INSULIN SYRINGES 29G X 1/2	174, 181	STELARA INTRAVENOUS	387
SAFETY INSULIN SYRINGES 30G X 1/2	174, 181	STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML	385, 386
SAFETY INSULIN SYRINGES 30G X 5/16	174, 181	STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	385, 386
SAFETY PEN NEEDLES 30G X 5 MM	174, 181	STERILE GAUZE PAD 2	175, 181
SAFETY PEN NEEDLES 30G X 8 MM	174, 181	STERILE PAD 2.....	175, 181
sapropterin dihydrochloride oral tablet...	306	STIVARGA	279
SB ALCOHOL PREP PAD 70 %... 174, 181		STRENSIQ	34, 35
SB INSULIN SYRINGE 29G X 1/2	174, 181	sunitinib malate.....	333
SB INSULIN SYRINGE 30G X 5/16 ...	174, 181	SURE COMFORT ALCOHOL PREP PAD 70 %	175, 181
SB INSULIN SYRINGE 31G X 5/16 ...	174, 181	SURE COMFORT INSULIN SYRINGE 28G X 1/2.....	175, 181
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG.....	33	SURE COMFORT INSULIN SYRINGE 29G X 1/2.....	175, 181
SECURESAFE INSULIN SYRINGE 29G X 1/2.....	174, 175, 181	SURE COMFORT INSULIN SYRINGE 30G X 1/2.....	175, 181
SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM.....	175, 181	SURE COMFORT INSULIN SYRINGE 30G X 5/16.....	175, 181
SELARSDI	388, 389, 390, 391	SURE COMFORT INSULIN SYRINGE 31G X 1/4.....	175, 181
SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG.....	326, 327	SURE COMFORT INSULIN SYRINGE 31G X 5/16.....	175, 181
SIGNIFOR	257	SURE COMFORT PEN NEEDLES 29G X 12.7MM	175, 181
sildenafil citrate oral tablet 20 mg ..	315, 316	SURE COMFORT PEN NEEDLES 30G X 8 MM	175, 181
SIRTURO	44		
SKYRIZI.....	297, 298		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

SURE COMFORT PEN NEEDLES 31G X 5 MM	175, 181	testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)	347
SURE COMFORT PEN NEEDLES 31G X 6 MM	175, 181	testosterone enanthate intramuscular solution.....	348
SURE COMFORT PEN NEEDLES 31G X 8 MM	175, 181	testosterone gel 1.62 % transdermal	346
SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC).....	175, 181	testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%).....	346
SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)	175, 181	tetrabenazine	349
SURE COMFORT PEN NEEDLES 32G X 6 MM	175, 181	TEVIMBRA.....	351
SURE-JECT INSULIN SYRINGE 31G X 5/16	175, 181	THALOMID	350
SURE-PREP ALCOHOL PREP PAD 70 %	175, 181	THERAGAUZE PAD 2.....	175, 181
SURGICAL GAUZE SPONGE PAD 2	175, 181	TIBSOVO	188
SYMPAZAN.....	73	TIGLUTIK.....	291
SYNRIBO	248	TIVDAK	352
T		TODAYS HEALTH PEN NEEDLES 29G X 12MM.....	175, 181
TABRECTA	66	TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM	176, 181
tadalafil oral tablet 2.5 mg, 5 mg	335	TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM.....	176, 181
TAFINLAR ORAL CAPSULE	79	TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM.....	176, 181
TAFINLAR ORAL TABLET SOLUBLE	80	TOPCARE ULTRA COMFORT INS SYR 29G X 1/2.....	176, 181
TAGRISSO	252	TOPCARE ULTRA COMFORT INS SYR 30G X 5/16.....	176, 181
TALVEY.....	337	TOPCARE ULTRA COMFORT INS SYR 31G X 5/16.....	176, 181
TALZENNA	336	torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg	125
TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG.....	230	TRAMADOL HCL ORAL SOLUTION	367
TAVNEOS	37	TRAZIMERA	374
TAZVERIK.....	339	TRELSTAR MIXJECT	379
TECHLITE INSULIN SYRINGE 29G X 1/2	175, 181	TREMFYA INTRAVENOUS	149, 150
TECHLITE PEN NEEDLES 32G X 4 MM	175, 181	TREMFYA ONE-PRESS.....	149, 150
TECVAYLI.....	341	TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML	149, 150
TEPMETKO	344	TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	149, 150
TERIPARATIDE SUBCUTANEOUS SOLUTION PEN-INJECTOR 620 MCG/2.48ML	345	tretinoin external cream	364
TERUMO INSULIN SYRINGE 29G X 1/2	175, 181	trientine hcl oral capsule 250 mg.....	377

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

TRUE COMFORT ALCOHOL PREP		TRUEPLUS 5-BEVEL PEN NEEDLES	
PADS PAD 70 %.....	176, 181	29G X 12.7MM.....	176, 181
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
30G X 1/2.....	176, 181	31G X 5 MM.....	177, 181
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
30G X 5/16.....	176, 181	31G X 6 MM.....	177, 181
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
31G X 5/16.....	176, 181	31G X 8 MM.....	177, 181
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
32G X 5/16.....	176, 181	32G X 4 MM.....	177, 181
TRUE COMFORT PEN NEEDLES 31G X		TRUEPLUS INSULIN SYRINGE 28G X	
5 MM	176, 181	1/2	177, 181
TRUE COMFORT PEN NEEDLES 31G X		TRUEPLUS INSULIN SYRINGE 29G X	
6 MM	176, 181	1/2	177, 181
TRUE COMFORT PEN NEEDLES 32G X		TRUEPLUS INSULIN SYRINGE 30G X	
4 MM	176, 181	5/16	177, 181
TRUE COMFORT PRO ALCOHOL PREP		TRUEPLUS INSULIN SYRINGE 31G X	
PAD 70 %	176, 181	5/16	177, 181
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 29G X 12MM	
30G X 1/2.....	176, 181	177, 181
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 5 MM	
30G X 5/16.....	176, 181	177, 181
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 6 MM	
31G X 5/16.....	176, 181	177, 181
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 8 MM	
32G X 5/16.....	176, 181	177, 181
TRUE COMFORT PRO PEN NEEDLES		TRUEPLUS PEN NEEDLES 32G X 4 MM	
31G X 5 MM.....	176, 181	177, 181
TRUE COMFORT PRO PEN NEEDLES		TRULICITY SUBCUTANEOUS	
31G X 6 MM.....	176, 181	SOLUTION AUTO-INJECTOR	145
TRUE COMFORT PRO PEN NEEDLES		TRUQAP ORAL TABLET	65
31G X 8 MM.....	176, 181	TRUQAP TABLET THERAPY PACK 160	
TRUE COMFORT PRO PEN NEEDLES		MG ORAL	65
32G X 4 MM.....	176, 181	TRUXIMA.....	300
TRUE COMFORT PRO PEN NEEDLES		TUKYSA ORAL TABLET 150 MG, 50	
32G X 5 MM.....	176, 181	MG	380
TRUE COMFORT PRO PEN NEEDLES		TURALIO	267
32G X 6 MM.....	176, 181	TYENNE.....	358, 359, 360, 361
TRUE COMFORT PRO PEN NEEDLES		TYMLOS	1
33G X 4 MM.....	176, 181	U	
TRUE COMFORT PRO PEN NEEDLES		UBRELVY.....	381
33G X 5 MM.....	176, 181	ULTICARE INSULIN SAFETY SYR 29G	
TRUE COMFORT PRO PEN NEEDLES		X 1/2.....	177, 181
33G X 6 MM.....	176, 181	ULTICARE INSULIN SYRINGE 28G X	
		1/2	177, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

ULTICARE INSULIN SYRINGE 29G X 1/2	177, 181	ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16.....	178, 181
ULTICARE INSULIN SYRINGE 30G X 1/2	177, 181	ULILET ALCOHOL SWABS PAD ...	178, 181
ULTICARE INSULIN SYRINGE 30G X 5/16	177, 181	ULILET INSULIN SYRINGE 30G X 1/2	178, 181
ULTICARE INSULIN SYRINGE 31G X 1/4	177, 181	ULILET INSULIN SYRINGE 30G X 5/16	178, 181
ULTICARE INSULIN SYRINGE 31G X 5/16	177, 181	ULILET INSULIN SYRINGE 31G X 1/4	178, 181
ULTICARE MICRO PEN NEEDLES 32G X 4 MM.....	178, 181	ULILET INSULIN SYRINGE 31G X 15/64	178, 181
ULTICARE MINI PEN NEEDLES 30G X 5 MM	178, 181	ULILET INSULIN SYRINGE 31G X 5/16	178, 181
ULTICARE MINI PEN NEEDLES 31G X 6 MM	178, 181	ULILET INSULIN SYRINGE SHORT 30G X 1/2.....	178, 181
ULTICARE MINI PEN NEEDLES 32G X 6 MM	178, 181	ULILET INSULIN SYRINGE SHORT 30G X 5/16.....	178, 181
ULTICARE PEN NEEDLES 29G X 12.7MM (OTC).....	178, 181	ULILET INSULIN SYRINGE SHORT 31G X 5/16.....	178, 181
ULTICARE PEN NEEDLES 29G X 12.7MM (RX)	178, 181	ULILET PEN NEEDLE 29G X 12.7MM	178, 181
ULTICARE PEN NEEDLES 31G X 5 MM	178, 181	ULILET PEN NEEDLE 31G X 5 MM	179, 181
ULTICARE SHORT PEN NEEDLES 30G X 8 MM.....	178, 181	ULILET PEN NEEDLE 31G X 8 MM	179, 181
ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC).....	178, 181	ULILET PEN NEEDLE 32G X 4 MM	179, 181
ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)	178, 181	ULTRA COMFORT INSULIN SYRINGE 30G X 5/16.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM.....	178, 181	ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM.....	178, 181	ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM.....	178, 181	ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM.....	178, 181	ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM.....	178, 181	ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2.....	179, 181
ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM.....	178, 181	ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16.....	179, 181
ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2.....	178, 181	ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16.....	179, 181

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

ULTRA FLO INSULIN SYRINGE 29G X 1/2	179, 181	UNIFINE OTC PEN NEEDLES 31G X 5 MM	180, 181
ULTRA FLO INSULIN SYRINGE 30G X 1/2	179, 181	UNIFINE OTC PEN NEEDLES 32G X 4 MM	180, 181
ULTRA FLO INSULIN SYRINGE 30G X 5/16	179, 181	UNIFINE PEN NEEDLES 32G X 4 MM	180, 181
ULTRA FLO INSULIN SYRINGE 31G X 5/16	179, 181	UNIFINE PENTIPS 29G X 12MM	180, 181
ULTRA THIN PEN NEEDLES 32G X 4 MM	179, 181	UNIFINE PENTIPS 31G X 6 MM.	180, 181
ULTRACARE INSULIN SYRINGE 30G X 1/2	179, 181	UNIFINE PENTIPS 31G X 8 MM.	180, 181
ULTRACARE INSULIN SYRINGE 30G X 5/16	179, 181	UNIFINE PENTIPS PLUS 29G X 12MM	180, 181
ULTRACARE INSULIN SYRINGE 31G X 5/16	179, 180, 181	UNIFINE PENTIPS PLUS 31G X 6 MM	180, 181
ULTRACARE PEN NEEDLES 31G X 5 MM	180, 181	UNIFINE PENTIPS PLUS 32G X 4 MM	180, 181
ULTRACARE PEN NEEDLES 31G X 6 MM	180, 181	UNIFINE PENTIPS PLUS 32G X 4 MM	180, 181
ULTRACARE PEN NEEDLES 31G X 8 MM	180, 181	UNIFINE PROTECT PEN NEEDLE 30G X 5 MM	180, 181
ULTRACARE PEN NEEDLES 32G X 4 MM	180, 181	UNIFINE PROTECT PEN NEEDLE 30G X 8 MM	180, 181
ULTRACARE PEN NEEDLES 32G X 5 MM	180, 181	UNIFINE PROTECT PEN NEEDLE 32G X 4 MM	180, 181
ULTRACARE PEN NEEDLES 32G X 6 MM	180, 181	UNIFINE PROTECT PEN NEEDLE 32G X 4 MM	180, 181
ULTRACARE PEN NEEDLES 33G X 4 MM	180, 181	UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	180, 181
ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2.....	179, 181	UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	180, 181
ULTRA-THIN II INS SYR SHORT 30G X 5/16	179, 181	UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	180, 181
ULTRA-THIN II INS SYR SHORT 31G X 5/16	179, 181	UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	180, 181
ULTRA-THIN II INSULIN SYRINGE 29G X 1/2.....	179, 181	UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	180, 181
ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM.....	179, 181	UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	180, 181
ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM.....	179, 181	UNIFINE ULTRA PEN NEEDLE 31G X 5 MM	180, 181
ULTRA-THIN II PEN NEEDLES 29G X 12.7MM	179, 181	UNIFINE ULTRA PEN NEEDLE 31G X 6 MM	180, 181
		UNIFINE ULTRA PEN NEEDLE 31G X 8 MM	180, 181
		UNIFINE ULTRA PEN NEEDLE 32G X 4 MM	180, 181
		UPTRAVI INTRAVENOUS.....	311
		UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200	

Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

MCG, 400 MCG, 600 MCG, 800 MCG	VONJO	254
..... 311	VORANIGO	405
UPTRAVI TITRATION	voriconazole oral suspension reconstituted	
311	406
V	VOSEVI	322, 323
VALCHLOR	VOWST	127
217	VP INSULIN SYRINGE 29G X 1/2	181
VALUE HEALTH INSULIN SYRINGE	VUMERITY	94
29G X 1/2	VYALEV SUBCUTANEOUS SOLUTION	
180, 181	12-240 MG/ML	135
VANFLYTA	VYLOY	410
278	W	
VANISHPOINT INSULIN SYRINGE 29G	WEBCOL ALCOHOL PREP LARGE PAD	
X 5/16	70 %	181
180, 181	WEGMANS UNIFINE PENTIPS PLUS	
VANISHPOINT INSULIN SYRINGE 30G	31G X 8 MM	181
X 3/16	WELIREG	47
180, 181	WINREVAIR	330
VANISHPOINT INSULIN SYRINGE 30G	X	
X 5/16	XALKORI ORAL CAPSULE	77
180, 181	XALKORI ORAL CAPSULE SPRINKLE	
VEGZELMA	150 MG, 20 MG, 50 MG	78
52	XDEMVY	211
VENCLEXTA ORAL TABLET 10 MG,	XELJANZ	362, 363
100 MG, 50 MG	XELJANZ XR	362, 363
400	XERMELO	343
VENCLEXTA STARTING PACK	XGEVA	89
400	XIFAXAN ORAL TABLET 200 MG, 550	
VEOZAH	MG	288
131	XOLAIR	249, 251
VERIFINE INSULIN PEN NEEDLE 29G	XOSPATA	142
X 12MM	XPOVIO (100 MG ONCE WEEKLY)	
180, 181	ORAL TABLET THERAPY PACK 50	
VERIFINE INSULIN PEN NEEDLE 31G	MG	312
X 5 MM	XPOVIO (40 MG ONCE WEEKLY) ORAL	
180, 181	TABLET THERAPY PACK 10 MG, 40	
VERIFINE INSULIN PEN NEEDLE 32G	MG	312
X 6 MM	XPOVIO (40 MG TWICE WEEKLY)	
180, 181	ORAL TABLET THERAPY PACK 40	
VERIFINE INSULIN SYRINGE 29G X 1/2	MG	312
.....	XPOVIO (60 MG ONCE WEEKLY) ORAL	
180, 181	TABLET THERAPY PACK 60 MG..	312
VERIFINE INSULIN SYRINGE 31G X	XPOVIO (60 MG TWICE WEEKLY)...	312
5/16	XPOVIO (80 MG ONCE WEEKLY) ORAL	
180, 181	TABLET THERAPY PACK 40 MG..	312
VERIFINE PLUS PEN NEEDLE 31G X 5		
MM		
181		
VERIFINE PLUS PEN NEEDLE 31G X 8		
MM		
181		
VERIFINE PLUS PEN NEEDLE 32G X 4		
MM		
181		
VERQUVO		
401		
VERZENIO		
6		
vigabatrin		
402		
vigadrone		
402		
vigpoder		
402		
VITRAKVI ORAL CAPSULE 100 MG, 25		
MG		
192		
VITRAKVI ORAL SOLUTION		
192		
VIVIMUSTA		
48		
VIZIMPRO		
81		

Provider Partners Health Plan

2025 Formulary – Prior Authorization Criteria

XPOVIO (80 MG TWICE WEEKLY)... 312
 XTANDI ORAL CAPSULE..... 114, 115
 XTANDI ORAL TABLET 40 MG, 80 MG
 114, 115
 XYOSTED 348

Y

YERVOY 186
 YESINTEK 392, 393, 394, 395
 YONSA 8
 YUFLYMA (1 PEN)..... 14, 15, 16
 YUFLYMA (2 SYRINGE)..... 14, 15, 16
 YUFLYMA-CD/UC/HS STARTER . 14, 15,
 16

Z

ZEJULA ORAL CAPSULE 234

ZEJULA ORAL TABLET 234
 ZELBORAF 399
 ZEVRX STERILE ALCOHOL PREP PAD
 PAD 70 % 181
 ZIIHERA 407
 ZIRABEV 54
 ZOLADEx 148
 ZTALMY 140
 ZTLIDO 207
 ZURZUVAE ORAL CAPSULE 20 MG, 25
 MG, 30 MG 411
 ZYDELIG 153
 ZYKADIA ORAL TABLET 68
 ZYNLONTA 209
 ZYNYZ 284